Poster Presentations Session I - Monday May 17, 2010

Click on the topic below to view posters

POSTER PRESENTATIONS SESSION I
SET-UP: Monday, May 17, 2010 – 7:30AM – 8:00AM
POSTER DISPLAY HOURS: Monday, May 17, 2010 – 8:00AM – 8:30PM
POSTER AUTHOR DISCUSSION HOUR: Monday, May 17, 20106:30PM – 7:30PM
DISMANTLE: Monday, May 17, 2010 – 8:30PM – 9:00PM

CONCEPTUAL PAPERS & RESEARCH ON METHODS Clinical Outcomes Methods

PMC1

EVALUATING CLINICIAN REPORTED OUTCOME (CRO) ENDPOINTS FOR FDA REGULATORY APPROVALS

 

Nixon A, Gallop K
Oxford Outcomes Ltd, Oxford, Oxon, UK

CONCEPTUAL PAPERS & RESEARCH ON METHODS Cost Methods

PMC2

REVIEW OF PHARMACOECONOMIC RECOMMENDATIONS FOR THE DEFINITION OF A SOCIETAL PERSPECTIVE

 

Fisher M, Alnwick K
Heron Evidence Development Limited, Luton, UK

PMC3

REVIEW OF COST EFFECTIVENESS ANALYSES THAT INCORPORATE NUMBER NEEDED TO TREAT/HARM VALUES

 

Raisch DW, Nawarskas JJ
University of New Mexico College of Pharmacy, Albuquerque, NM, USA

PMC4

THE DERIVATION OF TRICARE SPECIFIC CONSUMER PRICE INDICES FOR PRESCRIPTION DRUGS

 

Summers CR
TRICARE Management Activity, Falls Church, VA, USA

PMC5

VALIDATING A WEB-BASED INCREMENTAL COST-EFFECTIVENESS SOFTWARE PROGRAM THAT USES A MARKOV TRANSITION PROBABILITY MATRIX ANALYSIS MODEL

 

McGhan W, Zaveri V, Willey VJ, Gohil N
University of the Sciences in Philadelphia, Philadelphia, PA, USA

PMC6

USE OF CLINICAL SIMULATION CENTERS TO CONDUCT PATIENT-CENTERED TIME-AND-MOTION SIMULATIONS AS A BASIS FOR ECONOMIC ANALYSIS

 

Nickman N, Haak S, Kim J
University of Utah, Salt Lake City, UT, USA

PMC7

ESTIMATING TIME-PROFILED ECONOMIC BURDEN OF ILLNESS

 

Cao Z1, Song X1, Mark T2
1Thomson Reuters, Cambridge , MA, USA, 2Thomson Reuters, Washington, DC, USA

CONCEPTUAL PAPERS & RESEARCH ON METHODS Databases & Management Methods

PMC8

THE EFFECT OF LENGTH OF OBSERVATION AND CLAIMS DATA TYPE ON ESTIMATES OF COMORBIDITIES AMONG MEDICAID BENEFICIARIES

 

Banahan III BF, Pace PF
University of Mississippi, Oxford, MS, USA

PMC9

DATA SCAFFOLDING: A PRAGMATIC APPROACH TO STRUCTURING A LITERATURE REVIEW SPREADSHEET TO MAXIMIZE INFORMATION, FACILITATE REVIEW AND SUPPORT ANALYSIS

 

Ogden K1, Hansen R1, Rattana S2, Neil N1
1ICON Clinical Research, Lifecycle Sciences Group, San Francisco, CA, USA, 2ICON Clinical Research, Lifecycle Sciences Group, Chicago, IL, USA

PMC10

RATIONALE AND DEVELOPMENT OF AN ONLINE DIRECTORY OF DATABASE PROFILES FOR PHARMACOEPIDEMIOLOGY, OUTCOMES, AND POPULATION RESEARCH

 

Kamani SA, Goehring Jr EL, Singh VP, Nguyen-Khoa BA, Kapasi AJ, Jones JK
DGI, Inc., Arlington, VA, USA

PMC11

CAP DATABASE - PROVISION OF OUTPATIENT PROCEDURE DATA IN A UNIFIED, STANDARDIZED LANGUAGE

 

Endel G, Weisser A
Head Association of the Austrian Social Insurance Companies, Vienna, Austria

CONCEPTUAL PAPERS & RESEARCH ON METHODSModeling Methods

PMC12

RULING OUT EXTENDLY DOMINATED OPTIONS USING AN ICER MATRIX

 

O'Day K, Meissner B, Bramley T
Xcenda, Palm Harbor, FL, USA

PMC13

THE COST-EFFECTIVENESS SENSITIVITY CURVE: QUANTIFYING THE EFFECT OF INDIVIDUAL PARAMETER UNCERTAINTY IN A PROBABILISTIC MODEL

 

O'Day K, Meissner B, Bramley T
Xcenda, Palm Harbor, FL, USA

PMC14

MEDICATION LABEL EVALUATION PROCESS MODEL: USING THE STRUCTURAL EQUATION MODELING APPROACH TO BETTER PREDICT PURCHASE INTENTION

 

Dwibedi N, Sansgiry S
University of Houston, Houston, TX, USA

PMC15

SYNCHRONIZATION OF RANDOM NUMBER STREAMS GREATLY ENHANCES EFFICIENCY OF PROBABILISTIC MODELS

 

Smolen LJ, Klein RW
Medical Decision Modeling Inc., Indianapolis, IN, USA

PMC16

REVIEW OF COST EFFECTIVENESS STUDIES OF HIGH BUDGET IMPACT DRUGS

 

Aggarwal S1, White N2, Stevens CA3
1PAREXEL Consulting, Bethesda, MD, USA, 2PAREXEL Consulting, Centreville, VA, USA, 3PAREXEL Consulting, Waltham, MA, USA

CONCEPTUAL PAPERS & RESEARCH ON METHODS Patient-Reported Outcomes Studies
PMC17

A COMPARISON OF THE DISCRIMINTATIVE AND EVALUATIVE PROPERTIES OF THE SF-36 AND THE SF-6D INDEX

 

Mutebi A1, Brazier J2, Walters S2
1University of Arizona, Tucson, AZ, USA, 2University of Sheffield, Sheffield, UK

PMC18

ELECTRONIC PRO VERSUS PAPER PRO: WHAT DO THE PATIENTS THINK?

 

Ross J, Marcovitz M
Almac Clinical Technologies, Yardley, PA, USA

PMC19

DIMENSIONS CHARACTERIZING GOOD HEALTH BY CHINESE IN CHINA

 

Li M1, Bao Z2, Zhou J2, Luo N3
1China Pharmaceutical University, Nanjing, Jiangsu, China, 2The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China, 3National University of Singapore, Singapore, Singapore

PMC20

THE TRANSLATION AND LINGUISTIC VALIDATION OF THE EQ-5D VISUAL ANALOGUE SCALE (VAS)

 

Clough LA, Ashcroft-Jones AJ, Furtado T, Wild D
Oxford Outcomes Ltd, Oxford, Oxon, UK

PMC21

PATIENT-REPORTED OUTCOMES IN PRODUCT DEVELOPMENT GUIDANCE

 

Mordin M1, Lewis S2, Gnanasakthy A3, Demuro-Mercon C2, Copley-Merriman K1, Fehnel S2
1RTI Health Solutions, Ann Arbor, MI, USA, 2RTI Health Solutions, Research Triangle Park, NC, USA, 3Novartis Pharma, East Hanover, NJ, USA

PMC22

THE IMPACT OF A HOST COUNTRY'S CULTURE ON IMMIGRANT LANGUAGE

 

Hergibo P1, Plowright R2, Bradley C2, Weatherley BD3, Gekkieva M4, Unemori E5, Conway K1
1MAPI Institute, Lyon, France, 2Royal Holloway University of London, Surrey, UK, 3Momentum Research Inc, Durham, NC, USA, 4Novartis Pharma AG, Basel, Switzerland, 5Corthera, San Mateo, CA, USA

PMC23

A UNIVERSAL SCORING SYSTEM FOR EQ-5D : A VASTLY SIMPLER SOLUTION

 

Kind P
University of York, York, UK

PMC24

THE EFFECT OF FRAMING ON PREFERENCES FOR MAXIMIZING QALYS

 

Turpcu AH1, Le QA2, Bleichrodt H3, Doctor J2
1University of Southern California, Los Angeles, CA, USA, 2USC School of Pharmacy, Los Angeles, CA, USA, 3Erasmus University, Rotterdam, The Netherlands

PMC25

PATIENT PREFERENCES FOR ADHERENCE TOOLS ACROSS 10 MEDICAL CONDITIONS

 

Cascade E1, Rosen SH2, Plummer R3, Bharmal M4
1iGuard, Falls Church, VA, USA, 2Quintiles, Parsippany, NJ, USA, 3iGuard, Inc, Princeton, NJ, USA, 4Quintiles, Falls Church, VA, USA

PMC26

EVALUATING TREATMENT SATISFACTION ENDPOINT EVIDENCE FOR EMEA REGULATORY APPROVALS

 

Nixon A, Quadri N, Gallop K
Oxford Outcomes Ltd, Oxford, Oxon, UK

PMC27

HARMONISATION AS PART OF THE TRANSLATION AND LINGUISTIC PROCESS: WHAT IS THE OPTIMAL METHOD?

 

Furtado T1, Wild D2
1Oxford Outcomes, Oxford, Oxon, UK, 2Oxford Outcomes Ltd, Oxford, Oxon, UK

PMC28

INITIAL EXPERIENCE WITH THE PROMIS MEASUREMENT SYSTEM IN CLINICAL POPULATIONS

 

Nerenz DR, Pietrantoni L, Schultz L, Garden B, Obeid L, Swartz A, Shatz R, Rubinfeld I
Henry Ford Hospital, Detroit, MI, USA

PMC29

PATIENT PREFERENCE WEIGHTS FOR BENEFIT-RISK ANALYSIS: A STATIN CASE STUDY

 

Johnson FR1, Hauber AB1, Gonzalez JM1, Levitan B2, Copland P3
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Johnson & Johnson PRD, Titusville, NJ, USA, 3Purdue Pharma L.P., Stamford, CT, USA

PMC30

AGREEMENT BETWEEN PROMIS GLOBAL HEALTH SCALE AND SF-36 SCORES AMONG SURGICAL PATIENTS

 

Nerenz DR, Pietrantoni L, Schultz L, Obeid L, Swartz A, Rubinfeld I, Velanovich V
Henry Ford Hospital, Detroit, MI, USA

PMC31

THE ROLE OF THE PATIENT VOICE IN HEALTH TECHNOLOGY ASSESSMENT

 

Gnanasakthy A1, DeMuro C2, Mordin M3, Copley-Merriman K3, Mauskopf J2
1Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 2RTI Health Solutions, Research Triangle Park, NC, USA, 3RTI-HS, Ann Arbor, MI, USA

PMC32

PATIENT SATISFACTION COMPARISONS BETWEEN PEDIATRICIANS AND OTHER PCPS: A MULTILEVEL CROSS-NATIONAL WEB BASED SURVEY STUDY

 

Chang J1, Patel I1, Feldman SR2, Balrkishnan R1
1University of Michigan at Ann Arbor, Ann Arbor, MI, USA, 2Wake Forest University School of Medicine, Winston Salem, NC, USA

PMC33

THE TRANSLATION AND LINGUISTIC VALIDATION OF THE EQ-5D ELECTRONIC VERSION (EQ-5D EPRO)

 

Ashcroft-Jones AJ1, Furtado T1, Wild D2
1Oxford Outcomes, Oxford, Oxon, UK, 2Oxford Outcomes Ltd, Oxford, Oxon, UK

PMC34

SUPPLEMENTAL METHODOLOGY FOR TRANSLATING INSTRUMENTS DEVELOPED IN A LANGUAGE OTHER THAN ENGLISH

 

Handa M1, Gawlicki M2, McKown S1, Lauritzen M1, Hasegawa N1
1Corporate Translations, Inc, Chicago, IL, USA, 2Corporate Translations, Inc, East Hartford, CT, USA

PMC35

ISSUES IN THE TRANSLATION AND LINGUISTIC VALIDATION OF EPRO AND IVRS INSTRUMENTS

 

Gordon-Stables R, Wild D
Oxford Outcomes Ltd, Oxford, Oxon, UK

PMC36

VALIDITY OF SELF-REPORT WITH RESPECT TO PRESCRIPTION MEDICATIONS AMONG PREGNANT WOMEN

 

Jaiswal P, Sarangarm P, Young B, Khan N, Dodd M, Phelan S, Rayburn W, Bakhireva L
University of New Mexico Health Sciences Center, Albuquerque, NM, USA

PMC37

PATIENT REPORTED OUTCOME RECALL PERIODS IN LIGHT OF THE FINAL FDA GUIDANCE

 

Wild D, Nixon A
Oxford Outcomes Ltd, Oxford, Oxon, UK

PMC38

DETERMINING MISSING DATA RULES FOR PROS: ALPHA-IF-ITEM-DELETED

 

Nelson L, Coon C, Williams V, Price M
RTI Health Solutions, Research Triangle Park, NC, USA

PMC39

TAPPING INTO A NEW DATA COLLECTION PARADIGM: USING DIRECT TO PATIENT PROGRAMS FOR MORE COST EFFECTIVE STUDY MANAGEMENT

 

Tandon R
PAREXEL International, Waltham, MA, USA

PMC40

INSTIGATING AND ENCOURAGING INDIVIDUAL HEALTH BEHAVIORS THROUGH TECHNOLOGY: A TRANSTHEORETICAL PROPOSITION

 

Ersin ÖH, Freitas EL, Schommer JC
University of Minnesota, Minneapolis, MN, USA

PMC41

PATIENT-REPORTED OUTCOMES IN CLINICAL RESEARCH: PRESENT STATUS AND A LOOK TO THE FUTURE

 

Hao Y
Mapi Values, Boston, MA, USA

PMC42

EXAMINATION OF THE DIFFERENCES IN PATIENT SATISFACTION BETWEEN FIRST VISIT AND RETURN VISITS: ANALYSIS OF A USA SELF-REPORTED SURVEY DATA

 

Iaconi AI1, Chang J1, Feldman SR2, Balkrishnan R1
1The University of Michigan, Ann Arbor, MI, USA, 2Wake Forest University, Winston-Salem, NC, USA

PMC43

EIGHT KEY EVIDENCES FOR CONTENT VALIDITY OF PATIENT REPORTED OUTCOME (PRO) INSTRUMENTS

 

Martin ML
Health Research Associates, Inc, Seattle, WA, USA

PMC44

AN EVALUATION OF THE STATISTICAL EFFICIENCY OF THE US POPULATION MEDIAN-BASED EQ-5D INDEX USING DATA FROM THE MEDICAL EXPENDITURE PANEL SURVEY

 

Luo X, Shaw JW, Pickard AS, Walton S
University of Illinois at Chicago, Chicago, IL, USA

CONCEPTUAL PAPERS & RESEARCH ON METHODS Statistical Methods

PMC45

INTEGRATED INTERPRETATION OF KAPPA WITH SENSITIVITY AND SPECIFICITY

 

Shimbo T1, Miyaki K1, Sakai M1, Takahashi O2, Ishizuka N1
1International Medical Center of Japan, Tokyo, Japan, 2St.Luke's Life Science Institute, Tokyo, Japan

PMC46

COMPARISON OF DIFFERENCE-IN-DIFFERENCE AND PROPENSITY SCORE METHODS IN REGRESSIONS WITH BINARY OUTCOMES

 

Cao Z1, Margolis J2, Mark T3
1Thomson Reuters, Cambridge, MA, USA, 2Thomson Reuters, Bala Cynwyd, PA, USA, 3Thomson Reuters, Washington, DC, USA

PMC47

STATISTICAL METHODS NEEDED IN HEALTH ECONOMICS

 

Gause D, Gause P
See-It-Analytics, Easton , PA, USA

CONCEPTUAL PAPERS & RESEARCH ON METHODS Study Design

PMC48

METHODS FOR IDENTIFYING CASE REPORTS OF SUSPECTED ADVERSE DRUG REACTIONS: AN EVALUATION OF THE EFFICIENCY OF ALTERNATIVE SEARCH STRATEGIES IN MEDLINE AND EMBASE

 

Michels SL, Ward A, Jones N
United BioSource Corp., Lexington, MA, USA

POSTER PRESENTATIONS SESSION I
SET-UP: Monday, May 17, 2010 – 7:30AM – 8:00AM
POSTER DISPLAY HOURS: Monday, May 17, 2010 – 8:00AM – 8:30PM
POSTER AUTHOR DISCUSSION HOUR: Monday, May 17, 20106:30PM – 7:30PM
DISMANTLE: Monday, May 17, 2010 – 8:30PM – 9:00PM

CANCER Clinical Outcomes Studies

PCN1

USE OF WHITE BLOOD CELL GROWTH FACTORS AND RISK OF ACUTE MYELOID LEUKEMIA OR MYELODYSPLASTIC SYNDROMES AMONG ELDERLY NON-HODGKIN'S LYMPHOMA PATIENTS

 

Gruschkus SK1, Lairson D2, Dunn JK3, Risser JM3, Du XL3
1Healthcare Informatics, a service of US Oncology, The Woodlands, TX, USA, 2University of Texas School of Public Health, Houston, TX, USA, 3University of Texas Houston School of Public Health, Houston, TX, USA

PCN2

DIABETIC MEDICATIONS AND ITS ASSOCIATION WITH MORTALITY IN HOSPITALIZED CANCER PATIENTS

 

Nowshad G1, Alam S2, Shah P3, Salahudeen A4
1University of Texas, School of Public Health, Houston, TX, USA, 2School of Public Health, UT Houston, Houston, TX, USA, 3Mayo Clinic,, MN, Rochester, MN, USA, 4The University of Texas M.D. Anderson Cancer Center, Houston, TX, Houston, TX, USA

PCN3

RELIABILITY OF CLINICIAN VS. CLINICIAN ADVERSE SYMPTOM REPORTING

 

Atkinson TM1, Sit L1, Coffey C2, Shaw M1, Fruscione M1, Lavene D1, Gönen M1, Li Y1, Basch E1
1Memorial Sloan-Kettering Cancer Center, New York, NY, USA, 2University of Kansas Medical Center, Lawrence, KS, USA

PCN4

INSULINS AND RISK OF CANCER AMONG TYPE 2 DIABETICS: A SYSTEMATIC REVIEW

 

Lu Z, Weiss Smith S
University of Maryland School of Pharmacy, Baltimore, MD, USA

PCN5

ASSESSMENT OF NEUROPATHY IN CLAIMS DATA AND THE ASSOCIATION WITH DOCETAXEL (DC) AND PACLITAXEL (PC) IN ADJUVANT BREAST CANCER (BC)

 

Burke JP1, Seal B2, Teitelbaum A3, Henk HJ1
1i3 Innovus, Eden Prairie, MN, USA, 2Sanofi-Aventis Pharmaceuticals, Bridgewater, NJ, USA, 3i3 Global, San Diego, CA, USA

PCN6

EVALUATION OF THE RELIABILITY OF ELECTRONIC MEDICAL RECORD DATA IN IDENTIFYING COMORBID CONDITIONS AMONG PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

 

Gruschkus SK1, Hoverman JR2, Muehlenbein CE3, Forsyth M4, Chen C1, Lopez W1, Lawson AH5, Pohl G3
1Healthcare Informatics, a service of US Oncology, The Woodlands, TX, USA, 2Texas Oncology, Dallas, TX, USA, 3Eli Lilly and Company and/or any of its subsidiaries, Indianapolis, IN, USA, 4Healthcare Informatics, The Woodlands, TX, USA, 5Eli Lilly and Company, Indianapolis, IN, USA

PCN7

A COMPARISON OF INTRAVENOUS AND ORAL FORMULATIONS OF FLUDARABINE IN THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA

 

Eaddy M1, Chen L2, DuBois R1, Davies EH3
1Xcenda, Palm Harbor, FL, USA, 2Sanofi-Aventis, Bridgewater, NJ, USA, 3Xcenda, Charlotte, NC, USA

PCN8

IMPACT OF 5-HT3-RECEPTOR ANTAGONIST STEP THERAPY ON CHEMOTHERAPY INDUCED NAUSEA AND VOMITING ASSOCIATED HOSPITAL AND EMERGENCY ROOM EVENTS

 

Hatoum HT1, Lin SJ2, Buchner D3, Cox D3, Powers A3
1Hind T. Hatoum & Company, Chicago, IL, USA, 2University of Illinois at Chicago, College of Pharmacy, Chicago, IL, USA, 3Eisai, Inc., Woodcliff Lake, NJ, USA

PCN9

USING PROPENSITY SCORES TO REDUCE SELECTION BIAS IN AN OBSERVATIONAL STUDY COMPARING RASBURICASE TO ALLOPURINOL IN THE US

 

Tangirala M1, Seal B2, Douglas D3, Cairo MS4
1Smith Hanley Consulting Group LLC, Lake Mary, FL, USA, 2Sanofi-Aventis Pharmaceuticals, Bridgewater, NJ, USA, 3Ernest Mario School of Pharmacy at Rutgers University, Piscataway, NJ, USA, 4Morgan Stanley Children's Hospital, Columbia University Medical Center, New York, NY, USA

PCN10

ESTIMATION OF G-CSF EFFECTIVENESS IN REDUCING NEUTROPENIA HOSPITALIZATION AMONG NON-HODGKIN'S LYMPHOMA (NHL) PATIENTS TREATED WITH ANTHRACYCLINE-BASED CHEMOTHERAPY

 

Pan X1, Brooks J2
1University of Iowa, Iowa City, IA, USA, 2Univ of Iowa, Iowa City, IA, USA

PCN11

ASSESSING THE TREATMENT EFFECT OF RASBURICASE ALONE VERSUS RASBURICASE AND ALLOPURINOL COMBINATION THERAPY USING PROPENSITY SCORES

 

Tangirala M1, Seal B2, Cairo MS3, Douglas D4
1Smith Hanley Consulting Group LLC, Lake Mary, FL, USA, 2Sanofi-Aventis Pharmaceuticals, Bridgewater, NJ, USA, 3Morgan Stanley Children's Hospital, Columbia University Medical Center, New York, NY, USA, 4Ernest Mario School of Pharmacy at Rutgers University, Piscataway, NJ, USA

PCN12

HORIZON SCANNING TO SUPPORT PRIORITY-SETTING FOR PROSPECTIVE COMPARATIVE EFFECTIVENESS RESEARCH (CER) IN CANCER GENOMICS

 

Thariani R1, Carlson J1, Wong W1, Garrison L2, Veenstra D1, Ramsey S3, Crowley J4, Baker L5, Barlow W4, Burke W1, Tunis SR6
1University of Washington, Seattle, WA, USA, 2University of Washington, Department of Pharmacy, Seattle, WA, USA, 3Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA, 4Cancer Research and Biostatistics, Seattle, WA, USA, 5Southwest Oncology Group, Ann Arbor, MI, USA, 6Center for Medical Technology Policy, Baltimore, MD, USA

PCN13

TAXANE USE AND NEUROPATHY IN EARLY STAGE BREAST CANCER PATIENTS – RESULTS FROM A US COMMUNITY ONCOLOGY CENTER

 

Zhao L1, Seal B2, Sullivan S3, Christiansen NP4
1eTeam. Inc, South Plainfield, NJ, USA, 2Sanofi-Aventis Pharmaceuticals, Bridgewater, NJ, USA, 3University of Washington, Seattle, WA, USA, 4Medical University of South Carolina, Charleston, SC, USA

PCN14

SYSTEMATIC REVIEW OF EFFICACY OUTCOMES REPORTED IN RANDOMISED CONTROLLED TRIALS OF FIRST-LINE (1L) THERAPIES FOR METASTATIC BREAST CANCER (MBC)

 

Harper C1, McCormick AL2, Sabaté E3
1Complete Medical Group, Glasgow, UK, 2Complete Medical Group, Macclesfield, UK, 3F. Hoffmann - La Roche Ltd, Basel, Switzerland

PCN15

STATIN USE AND THE RISK OF COLORECTAL CANCER: A POPULATION-BASED COHORT STUDY

 

Ceccarelli M1, Maio V2, Slabaugh SL2, Rabinowitz C2, Diamond JJ2
1Università degli Studi di Firenze, Firenze , Italy, 2Thomas Jefferson University, Philadelphia, PA, USA

PCN16

CANCER INCIDENCE IS INFLUENCED BY INSULIN DOSE AND METFORMIN IN TYPE 2 DIABETES

 

Currie CJ1, Gale EA2, Poole CD3
1Cardiff University, Cardiff, Wales, UK, 2Bristol University, Bristol, UK, 3Pharmatelligence, Cardiff, UK

PCN17

CASTRATION-RESISTANT PROSTATE CANCER (CRPC): A UK EPIDEMIOLOGY STUDY

 

Morgan C1, McEwan P1, Chamberlain G1, Cabrera C2, Parry D3
1Cardiff Research Consortium, Cardiff, UK, 2AstraZeneca, Mölndal , Sweden, 3AstraZeneca, Macclesfield, UK

PCN18

WITHDRAWN

 

 

PCN19

BREAST CANCER PATIENTS ARE TWICE AS LIKE TO DEVELOP ARTERIAL THROMBOEMBOLIC EVENTS AFTER DIAGNOSIS COMPARED TO CANCER-FREE WOMEN

 

Shantakumar S1, van Herk-Sukel MPP2, Nelson JJ1, Kamphuisen PW3, Abrahamson PE4, Penning-van Beest FJA2, Herings RMC2
1GlaxoSmithKline, Research Triangle Park, NC, USA, 2PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands, 3Academic Medical Center, Amsterdam, The Netherlands, 4Salmon Bay Epidemiology, Seattle, WA, USA

PCN20

INFUSION REACTIONS IN PATIENTS TREATED WITH ANTI-EGFR MONOCLONAL ANTIBODY THERAPIES FOR METASTATIC COLORECTAL CANCER: RATES AND IMPACT FROM LITERATURE REVIEW

 

Long S1, Song X1, Barber B2, Kassed CA3, Zhao Z2
1Thomson Reuters, Cambridge, MA, USA, 2Amgen, Inc, Thousand Oaks, CA, USA, 3Thomson Reuters, Washington, DC, USA

PCN21

REAL-WORLD CLINICAL OUTCOMES OF PATIENTS WITH TRIPLE NEGATIVE BREAST CANCER – RESULTS FROM A US LOCAL ONCOLOGY PRACTICE

 

Zhao L1, Chen L2, Sullivan SD3, Christiansen NP4
1eTeam. Inc, South Plainfield, NJ, USA, 2Sanofi-Aventis, Bridgewater, NJ, USA, 3University of Washington, Seattle, WA, USA, 4Medical University of South Carolina, Charleston, SC, USA

PCN22

DO GAPS IN TREATMENT CONTINUATION OF DOCETAXEL AFFECT OVERALL SURVIVAL? – RESULTS FROM A US LOCAL COMMUNITY PRACTICE

 

Zhao L1, Chen L2, Christiansen NP3, Sullivan SD4
1eTeam. Inc, South Plainfield, NJ, USA, 2Sanofi-Aventis, Bridgewater, NJ, USA, 3Medical University of South Carolina, Charleston, SC, USA, 4University of Washington, Pharmaceutical Outcomes Research and Policy Program, Seattle, WA, USA

PCN23

OVERALL SURVIVAL AND GAP IN DOCETAXEL TREATMENT CONTINUATION IN PATIENTS WITH METASTATIC PROSTATE CANCER – RESULTS FROM A US ONCOLOGY NETWORK

 

Chung H1, Chen L2, Sullivan SD3, Christiansen NP4
1Rutgers University, Piscataway, NJ, USA, 2Sanofi-Aventis, Bridgewater, NJ, USA, 3University of Washington, Pharmaceutical Outcomes Research and Policy Program, Seattle, WA, USA, 4Medical University of South Carolina, Charleston, SC, USA

PCN24

OVERALL SURVIVAL AND DOCETAXEL TREATMENT CYCLES IN PATIENTS WITH METASTATIC PROSTATE CANCER – RESULTS FROM A US ONCOLOGY NETWORK

 

Chung H1, Chen L2, Christiansen NP3, Sullivan SD4
1Rutgers University, Piscataway, NJ, USA, 2Sanofi-Aventis, Bridgewater, NJ, USA, 3Medical University of South Carolina, Charleston, SC, USA, 4University of Washington, Pharmaceutical Outcomes Research and Policy Program, Seattle, WA, USA

CANCER Cost Studies

PCN25

THE BUDGETARY IMPACT OF PEMETREXED MAINTENANCE THERAPY FOR ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER

 

Klein R1, Lawson AH2, Muehlenbein CE3, Liepa AM3, Wielage RC1, Babineaux S4, Koustenis AG3
1Medical Decision Modeling, Indianapolis, IN, USA, 2Eli Lilly and Company, Indianapolis, IN, USA, 3Eli Lilly and Company and/or any of its subsidiaries, Indianapolis, IN, USA, 4Eli Lilly and Company and/or any of its subsidiaries, Dublin, OH, USA

PCN26

BUDGET IMPACT ANALYSIS OF AN ORGANIZED BREAST CANCER SCREENING PROGRAM BASED ON ANNUAL MAMOGRAPHY FOR COLOMBIAN WOMEN

 

Hernández L1, Castillo M2
1United BioSource Corporation, Bogotá, Colombia, 2Universidad de los Andes, Bogotá, Colombia

PCN27

ESTIMATED IMPACT OF EVEROLIMUS ON ANNUAL DRUG EXPENDITURE IN THE TREATMENT OF ADVANCED RENAL CELL CARCINOMA IN A US HEALTH PLAN

 

Casciano R1, Chulikavit M1, Liu Z3, Rogerio J2
1Analytica International, New York, NY, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 3Novartis Pharmaceuticals Corporation, Florham Park, NJ, USA

PCN28

BUDGET IMPACT ANALYSIS OF NEW PROSTATE-SPECIFIC ANTIGEN ASSAY AND INDEX FOR PROSTATE CANCER DETECTION

 

Nichol MB1, Wu J1, An JJ1, Huang JT2, Frencher SK3, Jacobsen SJ4
1University of Southern California, Los Angeles, CA, USA, 2Beckman Coulter Inc, Brea, CA, USA, 3UCLA, RAND Institute, Los Angeles, CA, USA, 4Kaiser Permanente Southern California, Pasadena, CA, USA

PCN29

REAL WORLD DATA ON MULTIFRACTION (MFR) VERSUS SINGLE FRACTION (SFR) RADIOTHERAPY TO TREAT BONE METASTASIS: IMPACT IN COSTS FOR PRIVATE HEALTH CARE (PHC) PROVIDERS IN BRAZIL

 

Paladini LM, Clark LGO, Clark O, Pegoretti B, Engel T, Faleiros EJM
Evidencias, Campinas, Brazil

PCN30

EFFECTS OF ADDING CHEMOTHERAPY-SPECIFIC DISCONTINUATION AND DOSE DELAY/REDUCTIONS TO FEBRILE NEUTROPENIA PROPHYLAXIS DECISION MODELS

 

Ozer-Deniz S1, Taylor DC1, Hill GJ1, Skornicki ME1, Barron R2
1i3Innovus, Medford, MA, USA, 2AMGEN, Thousand Oaks, CA, USA

PCN31

COST COMPARISON OF INPATIENT AND OUTPATIENT HOSPITAL-BASED SERVICES BETWEEN TWO STRATEGIES FOR TREATMENT OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN A PUBLICLY FUNDED HEALTH CARE SYSTEM

 

Furlong W1, Rae CS2, Weitzman S3, Barr RD2
1Health Utilities Inc., Dundas, ON, Canada, 2McMaster University, Hamilton, ON, Canada, 3The Hospital for Sick Children, Toronto, ON, Canada

PCN32

RECENT ERYTHROPOIESIS STIMULATING AGENT (ESA) UTILIZATION AND COSTS IN MEDICARE PATIENTS WITH CANCER RECEIVING CHEMOTHERAPY (CRC)

 

Kokkotos FK1, Bailey RA2, Kerr M1, Shen S1, Senbetta M2, McKenzie RS2
1Trinity Partners, LLC, Waltham, MA, USA, 2Centocor Ortho Biotech Services, LLC, Horsham, PA, USA

PCN33

OPEN VERSUS LAPAROSCOPIC PROCEDURES FOR COLECTOMY SURGERY FOR PATIENTS WITH COLON RECTAL CANCER: AN ANALYSIS OF OPPORTUNITY COSTS, UNDER THE PERSPECTIVE OF A PRIVATE HOSPITAL IN BRAZIL

 

Nasciben V, Saggia MG
Johnson & Johnson, Sao Paulo-SP, Brazil

PCN34

ECONOMIC BURDEN OF MYELODYSPLASTIC SYNDROMES AMONG US MEDICARE BENEFICIARIES: INCREASED COSTS IN TRANSFUSION DEPENDENT PATIENTS

 

Goldberg SL1, Chen E2, Corral M3, Guo A4, Laouri M5
1John Theurer Cancer Center, Hackensack, NJ, USA, 2Quorum Consulting, San Francisco, CA, USA, 3Novartis Oncology, East Hanover, NJ, USA, 4Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 5Quorum Consulting Inc, San Francisco, CA, USA

PCN35

OUT OF POCKET EXPENSES FOR BREAST CANCER SURVIVORS: DIFFERENCES BY TIME SINCE DIAGNOSIS IN A RURAL POPULATION

 

Pisu M, Azuero A, McNees P, Burkhardt J, Meneses K
University of Alabama at Birmingham, Birmingham , AL, USA

PCN36

COST OF ILLNESS FOR PATIENTS WITH METASTATIC COLORECTAL CANCER

 

Song X1, Zhao Z2, Barber B2, Gregory C3, Cao Z1, Gao S2
1Thomson Reuters, Cambridge , MA, USA, 2Amgen, Inc, Thousand Oaks, CA, USA, 3Thomson Reuters, Washington, DC, USA

PCN37

BURDEN OF INPATIENT CASES OF ACUTE EXACERBATIONS OF COPD WITH LUNG CANCER IN THE UNITED STATES IN 2006

 

Perera P1, Skrepnek G2
1College of Pharmacy, University of Arizona, Tucson, AZ, USA, 2University of Arizona College of Pharmacy Center for Health Outcomes and PharmacoEconomic Research, Tucson, AZ, USA

PCN38

WITHDRAWN

 

 

PCN39

WITHDRAWN

 

 

PCN40

RETROSPECTIVE COST AND OUTCOME ANALYSIS OF BREAST CANCER PATIENTS TREATED IN A BRAZILIAN OUTPATIENT CANCER CENTER (OCC)

 

Teich N1, Souza CPR1, Teich V1, Cintra M1, Musacchio JG2, Vieira FM1
1MedInsight, Rio de Janeiro, Rio de Janeiro, Brazil, 2COI - Clinicas Oncológicas Integradas, Rio de Janeiro, Rio de Janeiro, Brazil

PCN41

HEALTH CARE COST OF BREAST CANCER: A CLAIMS DATA ANALYSIS

 

Fu AZ1, Chen L2, Christiansen NP3, Sullivan SD4
1Cleveland Clinic, Cleveland, OH, USA, 2Sanofi-Aventis, Bridgewater, NJ, USA, 3Medical University of South Carolina, Charleston, SC, USA, 4University of Washington, Pharmaceutical Outcomes Research and Policy Program, Seattle, WA, USA

PCN42

INDIRECT COST ASSOCIATED WITH BREAST CANCER TO US EMPLOYERS

 

Fu AZ1, Chen L2, Christiansen NP3, Sullivan SD4
1Cleveland Clinic, Cleveland, OH, USA, 2Sanofi-Aventis, Bridgewater, NJ, USA, 3Medical University of South Carolina, Charleston, SC, USA, 4University of Washington, Seattle, WA, USA

PCN43

INITIAL COSTS OF TREATMENT AMONG STAGE IV PROSTATE CANCER (PCA) CHEMOTHERAPY PATIENTS IN SEER-MEDICARE

 

Onukwugha E, Mullins CD1, Seal B2, Hussain A3
1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2Sanofi-Aventis Pharmaceuticals, Bridgewater, NJ, USA, 3University of Maryland School of Medicine, Baltimore, MD, USA

PCN44

ASSESSMENT OF HEALTH CARE UTILIZATION AND COST AMONG METASTATIC MELANOMA PATIENTS IN A US MANAGED CARE POPULATION

 

Ray S, Ganguli A, Luo Y, Xu Y
Abbott Laboratories, Abbott Park, IL, USA

PCN45

HEALTH CARE RESOURCE UTILIZATION (HRU) IN ADVANCED OVARIAN CANCER-FINDINGS FROM LINKED SEER-MEDICARE DATA

 

Parthan A1, Gao SK2, Song R3, Borker R2, Langeberg WJ2, Teitelbaum A3, Oglesby A2
1i3 Innovus, San Francisco, CA, USA, 2Amgen, Inc., Thousand Oaks, CA, USA, 3i3 Innovus, Eden Prairie, MN, USA

PCN46

FIRST YEAR INSURER AND PATIENT COSTS ASSOCIATED WITH HEPATOCELLULAR CARCINOMA DIAGNOSIS IN THE U.S. MANAGED CARE POPULATION

 

Tsong W, Ray S
Abbott Laboratories, Abbott Park, IL, USA

PCN47

COMPARISON OF HEALTHCARE RESOURCE UTILIZATION AND COSTS BETWEEN NILOTINIB AND DASATINIB AS SECOND LINE THERAPIES IN CHRONIC MYELOID LEUKEMIA (CML)

 

Wu EQ1, Bollu V2, Guo A2, Guerin A3, Tsaneva M1, Williams D2, Griffin JD4
1Analysis Group, Inc., Boston, MA, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 3Analysis Group, Ltee., Montreal, QC, Canada, 4Dana Farber Cancer Institute, Boston, MA, USA

PCN48

NON-ADHERENCE TO IMATINIB IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS IS ASSOCIATED WITH SHORT- AND LONG-TERM NEGATIVE IMPACTS ON HEALTH CARE RESOURCE UTILIZATION AND COSTS

 

Guerin A1, Bollu V2, Guo A2, Wu EQ3, Yu AP3, Sirulnik LA2, Griffin JD4
1Analysis Group, Ltee., Montreal, QC, Canada, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 3Analysis Group, Inc., Boston, MA, USA, 4Dana Farber Cancer Institute, Boston, MA, USA

PCN49

COSTS TO MEDICARE OF TREATING CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH ALEMTUZUMAB

 

Lafeuille MH1, Vekeman F2, Kerrigan M3, Wang ST4, Duh MS4
1Groupe d'analyse, Ltée, Montreal, QC, Canada, 2Analysis Group, Inc., Washington , DC, USA, 3GlaxoSmithKline, Philadelphia, PA, USA, 4Analysis Group, Inc., Boston, MA, USA

PCN50

COSTS OF TREATMENT WITH ANGIOGENESIS INHIBITORS (AIS) IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC): RESULTS FROM A MEDICAL CHART REVIEW STUDY

 

Oh WK1, McDermott DF2, Duh MS3, Antràs L3, Chen K3, Sarda SP3, Luka A3, Whittemore S3, Ramamurthy P3, Neary MP4, Choueiri TK5
1Mount Sinai School of Medicine, New York, NY, USA, 2Beth Israel Deaconess Medical Center, Boston, MA, USA, 3Analysis Group, Inc., Boston, MA, USA, 4GlaxoSmithKline, Collegeville, PA, USA, 5Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA, USA

PCN51

HEALTHCARE COSTS ASSOCIATED WITH ANGIOGENESIS INHIBITORS (AIS) AND MTOR INHIBITORS (MTORS) IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) TREATED AT US COMMUNITY ONCOLOGY CLINICS

 

Chen K1, Sarda SP1, Antràs L1, Whittemore S1, Luka A1, Ramamurthy P1, Scott J2, Fortner B2, Neary MP3, Duh MS1, Jolly P4
1Analysis Group, Inc., Boston, MA, USA, 2P4 Healthcare LLC, Ellicott City, MD, USA, 3GlaxoSmithKline, Collegeville, PA, USA, 4Georgia Cancer Specialists, Alpharetta, GA, USA

PCN52

HEALTH CARE COSTS ASSOCIATED WITH MULTIKINASE INHIBITORS (MKIS) FOR TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC) IN A CLINICAL PRACTICE SETTING IN ITALY

 

Paglino C1, Porta C1, Canipari C1, Antràs L2, Chen K2, Whittemore S2, Luka A2, Ramamurthy P2, Neary MP3, Duh MS2
1IRCCS San Matteo University Hospital Foundation, Pavia , Italy, 2Analysis Group, Inc., Boston, MA, USA, 3GlaxoSmithKline, Collegeville, PA, USA

PCN53

RETROSPECTIVE US CLAIMS DATABASE ANALYSIS OF THE COST OF SEQUENCING OF SORAFENIB AND SUNITINIB IN THE TREATMENT OF PATIENTS WITH RENAL CELL CARCINOMA (RCC)

 

Moyneur E1, Dorff T2, Barghout V3, Meyers S3, Hu J2, Quinn D2
1StatLog Consulting Inc., L'Ange-Gardien, QC, Canada, 2USC Keck School of Medicine, Los Angeles, CA, USA, 3Bayer HealthCare Pharmaceuticals Inc, Wayne, NJ, USA

PCN54

LOWER HEALTHCARE RESOURCE UTILIZATION ASSOCIATED WITH MANAGING NILOTINIB RELATED ADVERSE EVENTS IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS: EVIDENCE FROM A CLINICAL PRACTICE SETTING STUDY

 

Guerin A1, Bollu V2, Williams D2
1Analysis Group, Inc., Montreal, QC, Canada, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

PCN55

COSTS ASSOCIATED TO THE TREATMENT OF DIFFERENT STAGES OF MEXICAN PATIENTS WITH NON-HODGKIN LYMPHOMA

 

Balderas-Peña LMA1, Contreras I2, Garduno-Espinoza J3, Mould-Quevedo JF4, Sat-Muñoz D1, Morgan-Villela G5, Mariscal-Ramírez I1, Lomelí-García M5, Hernández-Chavez GA1, Garcés-Ruiz OM1
1Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, Mexico, 2Instituto Mexicano del Seguro Social, Delegación Cuauhtémoc.
Distrito Federal, Mexico, 3Secretaría de Salud. Hospital Infantil de México, México D.F., Mexico, 4Pfizer S.A. de C.V., México City, Mexico, 5Instituto Mexicano del Seguro Social. UMAE HE CMNO, Guadalajara, Jalisco, Mexico

PCN56

COSTS ASSOCIATED TO THE TREATMENT OF DIFFERENT STAGES OF MEXICAN BREAST CANCER PATIENTS

 

Balderas-Peña LMA1, Contreras I2, Mould-Quevedo JF3, Garduno-Espinoza J4, Sat-Muñoz D1, Morgan-Villela G5, Solano-Murillo P6, Mariscal-Ramírez I1, Lomelí-García M5, Hernández-Chavez GA1
1Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, Mexico, 2Instituto Mexicano del Seguro Social, Delegación Cuauhtémoc.
Distrito Federal, Mexico, 3Pfizer S.A. de C.V., México City, Mexico, 4Secretaría de Salud. Hospital Infantil de México, México D.F., Mexico, 5Instituto Mexicano del Seguro Social. UMAE HE CMNO, Guadalajara, Jalisco, Mexico, 6Instituto Mexicano de Seguro Social.UMAE HE CMNO, Guadalajara, Jalisco, Mexico

PCN57

COSTS ASSOCIATED TO THE TREATMENT OF DIFFERENT STAGES OF MEXICAN PATIENTS WITH COLORECTAL CANCER

 

Balderas-Peña LMA1, Contreras I2, Mould-Quevedo JF3, Morgan-Villela G4, Garduno-Espinoza J5, Sat-Muñoz D1, Solano-Murillo P6, Mariscal-Ramírez I1, Lomelí-García M4, Hernández-Chavez GA1
1Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, Mexico, 2Instituto Mexicano del Seguro Social, Delegación Cuauhtémoc.
Distrito Federal, Mexico, 3Pfizer S.A. de C.V., México City, Mexico, 4Instituto Mexicano del Seguro Social. UMAE HE CMNO, Guadalajara, Jalisco, Mexico, 5Secretaría de Salud. Hospital Infantil de México, México D.F., Mexico, 6Instituto Mexicano de Seguro Social.UMAE HE CMNO, Guadalajara, Jalisco, Mexico

PCN58

BEVACIZUMAB FOR THE TREATMENT OF METASTATIC BREAST CANCER: A COST-EFFECTIVENESS ANALYSIS

 

Fortune-Greeley A, Cornell P
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

PCN59

THE POTENTIAL ECONOMIC BENEFITS PROVIDED BY COMBINING CISPLATIN WITH SRC INHIBITOR KX1-004 FOR CANCER REGIMENS

 

Henderson D1, Hayward A2, Purdy C3, Magar R4
1Univesity at Buffalo, Buffalo, NY, USA, 2AHRM Inc., Buffalo, NY, USA, 3AHRM Incorporated, Buffalo, NY, USA, 4AHRM Inc., Raleigh, NC, USA

PCN60

COST-EFFECTIVENESS OF OXALIPLATIN AND IRINOTECAN BASED COMBINATION THERAPY COMPARED WITH 5FU/LV FOR THE TREATMENT OF US ELDERLY ADVANCED COLON CANCER PATIENTS

 

Hsiao FY1, Mullins CD1, Onukwugha E, Pandya NB2, Seal B3, Hanna N2
1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2University of Maryland Medical Center, Baltimore, MD, USA, 3Sanofi-Aventis Pharmaceuticals, Bridgewater, NJ, USA

PCN61

THE COST-EFFECTIVENESS OF CETUXIMAB USE AMONG ELDERLY METASTATIC COLORECTAL CANCER PATIENTS

 

Wei DB, Lin CC
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

PCN62

COST EFFECTIVENESS OF RADICAL PROSTATECTOMY VERSUS WATCHFUL WAITING FOR NON-SCREEN DETECTED PROSTATE CANCER: EXTRAPOLATING FROM THE SCANDINAVIAN TRIAL

 

Shteynshlyuger A
Washington University School of Medicine, St. Louis, MO, USA

PCN63

THE COST-EFFECTIVENESS OF MOHS MICROGRAPHIC SURGERY VERSUS SURGICAL EXCISION FOR THE TREATMENT OF NON-MELANOMA SKIN CANCER

 

Wilson L1, Paoli CJ1, Basu R1, Pregenzer M2, Jin M1
1University of California San Francisco, San Francisco, CA, USA, 2University of California Los Angeles Medical Center, Los Angeles, CA, USA

PCN64

COST-EFFECTIVENESS ANALYSIS OF SORAFENIB VERSUS BEST SUPPORTIVE CARE (BSC) IN ADVANCED HEPATOCELLULAR CARCINOMA (AHCC): THE PUBLIC HEALTH CARE SYSTEM PERSPECTIVE IN BRAZIL

 

Muszbeck N1, Munir U1, Vioix H1, Schiola A2, Valderrama A3, Teich V4
1United BioSource Corporation, London, UK, 2Bayer Healthcare, Sao Paulo, Brazil, 3Bayer, Cedar Grove, NJ, USA, 4MedInsight, Rio de Janeiro, Brazil

PCN65

A COST-EFFECTIVENESS ANALYSIS OF THE FIRST-LINE TREATMENT REGIMENS FOR MULTIPLE MYELOMA IN MACAO CHINA

 

Lee KK1, Lee VW1, Kuok KC2
1The Chinese University of Hong Kong, Hong Kong, China, 2Macao Polytechnic, Macao, China

PCN66

OPEN VERSUS LAPAROSCOPIC PROCEDURES FOR COLECTOMY SURGERY FOR PATIENTS WITH COLON RECTAL CANCER: A COST EFFECTIVENESS ANALYSIS, UNDER THE BRAZILIAN PRIVATE PAYER PERSPECTIVE

 

Nasciben V, Saggia MG
Johnson & Johnson, Sao Paulo-SP, Brazil

PCN67

COST-UTILITY OF KRAS MUTATION TESTING PRIOR TO TREATMENT OF METASTATIC COLORECTAL CANCER WITH CETUXIMAB MONOTHERAPY

 

Carlson JJ
University of Washington, Seattle, WA, USA

PCN68

COST-EFFECTIVENESS ANALYSIS OF SORAFENIB VERSUS BEST SUPPORTIVE CARE (BSC) IN ADVANCED HEPATOCELLULAR CARCINOMA (AHCC): THE PRIVATE HEALTH CARE SYSTEM PERSPECTIVE IN BRAZIL

 

Muszbeck N1, Vioix H1, Munir U1, Schiola A2, Valderrama A3, Teich V4
1United BioSource Corporation, London, UK, 2Bayer Healthcare, Sao Paulo, Brazil, 3Bayer, Cedar Grove, NJ, USA, 4MedInsight, Rio de Janeiro, Brazil

PCN69

COST-EFFECTIVENESS OF LENOGRASTYM ON NEUTROPENIA DURATION IN CHILDREN RECEIVING CHEMOTHERAPY FOR LEUKEMIA

 

Rutkowski J1, Derylo L1, Fedyna M1, Plisko R1, Lis J2, Wladysiuk M1
1HTA Consulting, Krakow, Poland, 2Sanofi-Aventis Sp. z o.o., Warsaw, Poland

PCN70

ECONOMIC EVALUATION ON THE USE OF PLERIXAFOR ALONGSIDE THE GRANULOCYTE-COLONY STIMULATING FACTOR (GCSF) IN PREPARATION FOR AN AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION ON PATIENTS WITH NON HODGKIN'S LYMPHOMA

 

Salinas G1, Idrovo J2, Zapata L3
1Hospital Infantil de México Federico Gómez, México, DF, Mexico, 2National Institute of Public Health, Cuernavaca, Morelos, Mexico, 3Guia Mark, Mexico, DF, Mexico

PCN71

COST EFFECTIVENESS ANALYSIS OF BREAST CANCER RISK REDUCTION THERAPY: COMPARING TAMOXIFEN AND RALOXIFENE

 

Poon JL, Hay J
University of Southern California, Los Angeles, CA, USA

PCN72

ECONOMIC EVALUATION OF SUNITINIB VS. INTERFERON- AND BEVACIZUMAB + INTERFERON- IN THE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (CCRM) – BRAZILIAN PRIVATE HEALTH SYSTEM PERSPECTIVE

 

Teich V1, Hashizume CM2, Marinho T1, Charbonneau C3, Naves A2
1Medinsight, Rio de Janeiro, RJ, Brazil, 2Pfizer Brazil, Sao Paulo, SP, Brazil, 3Pfizer, Inc., New York, NY, USA

PCN73

COST-EFFECTIVENESS ANALYSIS OF MULTIMODAL SCREENING FOR OVARIAN CANCER

 

Ding Y, Hay J
University of Southern California, Los Angeles, CA, USA

PCN74

COST-EFFECTIVENESS OF PROMOTORA LED HEALTH EDUCATION INTERVENTIONS TO INCREASE CERVICAL CANCER SCREENING AMONG LOW INCOME HISPANIC WOMEN

 

Lairson DR1, Chang YC2, Byrd TL3, Smith JL4, Wilson KM4
1University of Texas Houston School of Public Health, Houston, TX, USA, 2University of Texas School of Public Health, Houston, TX, USA, 3University of Texas School of Public Health, El Paso, TX, USA, 4Centers for Disease Control and Prevention, Atlanta, GA, USA

PCN75

COST-EFFECTIVENESS ANALYSIS OF EGFR MUTATION TESTING IN PATIENTS WITH ADVANCED NON SMALL-CELL LUNG CANCER (ANSCLC) TREATED WITH GEFITINIB OR CARBOPLATIN-PACLITAXEL

 

Arrieta O1, Anaya P2, López RJ2, Polanco AC2
1National Cancer Institute of Mexico, D.F., Mexico, 2AstraZeneca, Naucalpan, Mexico

PCN76

COST-EFFECTIVENESS OF WHITE BLOOD CELL GROWTH FACTOR USE AMONG ELDERLY NON-HODGKIN'S LYMPHOMA PATIENTS TREATED WITH CHEMOTHERAPY

 

Gruschkus SK1, Lairson DR2, Dunn JK2, Risser JM2, Du XL2
1Healthcare Informatics, a service of US Oncology, The Woodlands, TX, USA, 2University of Texas Houston School of Public Health, Houston, TX, USA

PCN77

COST-EFFECTIVENESS ANALYSIS OF ERLOTINIB IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN ROMANIA

 

Ciuleanu TE1, Dediu M2, Minea LN3, Baculea S4, Szkultecka-Debek M5
1Institute of Oncology “Prof. Dr. I. Chiricuta”, Cluj-Napoca, Romania, 2Oncologic Institute “Prof.Dr.Alexandru Trestioreanu”, Bucharest, Romania, 3Oncologic Institute “Prof.Dr.IAlexandru Trestioreanu”, Bucharest, Romania, 4Roche Romania, Bucharest, Romania, 5Roche Polska Sp. z o.o., Warszaw, Poland

PCN78

COST-EFFECTIVENESS MODELLING OF EPOETIN ALFA AND DARBEPOETIN ALFA IN THE TREATMENT OF CHEMOTHERAPY-RELATED ANAEMIA IN SWEDEN

 

Liwing J1, Näsman P2, Kernell H1, Gagnon DD3, Wu Y4
1Janssen-Cilag AB, Sollentuna, Sweden, 2Royal Institute of Technology, Stockholm, Sweden, 3J&J Pharmaceutical Services, L.L.C., Raritan, NJ, USA, 4Johnson & Johnson Pharmaceutical Services, LLC, Malvern, PA, USA

PCN79

REVIEW OF COST-EFFECTIVENESS STUDIES ON AROMATASE INHIBITORS FOR THE TREATMENT OF EARLY-STAGE BREAST CANCER

 

Topaloglu O, Unalp A
Johns Hopkins School of Public Health, Baltimore, MD, USA

PCN80

A SYSTEMIC REVIEW OF COST-EFFECTIVENESS OF PROSTATE-SPECIFIC ANTIGEN (PSA) IN PROSTATE CANCER SCREENING

 

An JJ1, Wu J1, Huang JT2, Nichol MB1
1University of Southern California, Los Angeles, CA, USA, 2Beckman Coulter Inc, Brea, CA, USA

PCN81

THE COST-EFFECTIVENESS ANALYSIS OF SEMI-ANNUAL SCREENING FOR HEPATOCELLULAR CARCINOMA IN PATIENTS WITH CHORNIC HEPATITIS B

 

Srisubat A1, Chaiwerawattana A2, Tunsakul S2, Sukarayodhin S2, Apiwanich C2, Sumetchotimaytha W2, Prasitthipayong A2,  Jaisathaporn K2, Karalak A2, Thaiyakul A1, Kapol N3, Sribundit N3, Chaiyakunapruk N4 1Institute of Medical Research and Technology Assessment, Phyathai, Thailand, 2National Cancer Institute, Rajthevee, Thailand, 3Silpakorn University, Nakorn Pathom, Thailand, 4Naresuan University, Phitsanulok, Thailand

PCN82

COST COMPARISON OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE VERSUS PEMETREXED AND CISPLATIN THERAPY IN PATIENTS WITH ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL CANCER IN GERMANY – AN UPDATED ANALYSIS

 

Bischoff HG1, Hermes A2, Heigener DF2, Cesaro-Tadic S3, Walzer S4, Nuijten M5
1Thoraxklinik, Heidelberg, Germany, 2Krankenhaus Grosshansdorf, Grosshansdorf, Germany, 3F. Hoffmann-La Roche Pharmaceuticals AG, Basel , Switzerland, 4F. Hoffmann-La Roche Ltd, Basel, Switzerland, 5Institute for Medical Technology Assessment, Rotterdam, The Netherlands

PCN83

COST-EFFECTIVENESS OF LENOGRASTYM ON NEUTROPENIA DURATION IN ADULTS RECEIVING CHEMOTHERAPY FOR SOLID TUMORS OR LYMPHOMAS

 

Rutkowski J1, Derylo L1, Fedyna M1, Plisko R1, Lis J2, Wladysiuk M1
1HTA Consulting, Krakow, Poland, 2Sanofi-Aventis Sp. z o.o., Warsaw, Poland

PCN84

COST EFFECTIVENESS ANALYSIS OF ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR AGENTS FOR TREATMENT REFRACTORY METASTATIC COLORECTAL CANCER

 

Chang JY1, Hay J2
1University of Southern California, Alhambra, CA, USA, 2University of Southern California, Los Angeles, CA, USA

PCN85

ECONOMIC MODELING FOR TREATMENT FAILURE PATIENTS USING MULTIPLE ROUNDS OF THERAPY AS COMPARATOR: CASE IN POINT LYMPHOMA DRUG CANDIDATE

 

Aggarwal S1, White N2, Stevens CA(3
1PAREXEL Consulting, Bethesda, MD, USA, 2PAREXEL Consulting, Centreville, VA, USA, 3PAREXEL Consulting, Waltham, MA, USA

PCN86

COST-EFFECTIVENESS OF CETUXIMAB COMBINED WITH RADIOTHERAPY FOR PATIENTS WITH LOCALLY ADVANCED HEAD AND NECK CANCER IN TAIWAN

 

Chan AL1, Leung HW2, Lin SJ3
1Chi Mei Medical Center, Tainan, Taiwan, 2Taipei Medical University-Shuang Ho Hospital,, Jhonghe City, Taiwan, 3Kaohsiung Medical University, Kaohsiung , Taiwan

PCN87

THE POTENTIAL IMPACT OF USING CHANGES IN SERUM HER2 LEVELS TO INITIATE THERAPY CHANGE IN HER2+ METASTATIC BREAST CANCER

 

Noy K1, Dejori M1, Ghosh P2, Suhail AM3, Leitzel K4, Lipton A4, Carney W5, Wittenberg G1
1Siemens Corporate Research, Princeton, NJ, USA, 2University of Erlangen-Nuremberg, Erlangen, Germany, 3VA Medical Center, Lebanon, PA, USA, 4Pennsylvania State University College of Medicine, Hershey, PA, USA, 5Siemens Healthcare Diagnostics, Cambridge, MD, USA

PCN88

COST-EFFECTIVENESS OF LENOGRASTIM NEUTROPENIA DURATION IN ADULTS RECEIVING CHEMOTHERAPY FOR LEUKEMIA

 

Rutkowski J1, Derylo L1, Fedyna M1, Plisko R1, Lis J2, Wladysiuk M1
1HTA Consulting, Krakow, Poland, 2Sanofi-Aventis Sp. z o.o., Warsaw, Poland

PCN89

COST EFFECTIVENESS ANALYSIS OF A CLINICAL PATHWAY FOR THE SURVEILLANCE OF HEPATOCARCINOMA IN COLOMBIA

 

Romero M, Arango C, Albanes J
Fundacion Salutia, bogota, Colombia

PCN90

BORTEZOMIB IS COST-EFFECTIVE FOR FIRST-LINE TREATMENT OF MULTIPLE MYELOMA IN SWEDEN

 

Rickert JB1, Hornberger J2, Liwing J3, Aschan J3, Gjönnes L4, Dhawan R5
1Cedar Associates LLC, Menlo Park, CA, USA, 2Cedar Associates LLC and Stanford University, Menlo Park, CA, USA, 3Janssen-Cilag AB, Sollentuna, Sweden, 4Jannssen-Cilag AS, Lysaker, Norway, 5Johnson & Johnson Pharmaceutical Services LLC, Raritan, NJ, USA

PCN91

VALIDATION OF HEALTH OUTCOMES RESEARCH OF CANCER

 

Choi S
Health Outcomes Focus, Goleta, CA, USA

PCN92

VALUATION OF CLINICO-ECONOMIC EFFECTIVNESS OF THEATMENT OF CHILDREN WITH THE NON-HODGKIN LYMPHOMAS (NHLS) ACCORDING TO THE NHL-BFM-95 PROTOCOL

 

Dunaev SM
Izhevsk state medical academy, Izhevsk, Udmurt republic, Russia

PCN93

COST-EFFECTIVENESS ANALYSIS OF BENDAMUSTINE COMPARED TO ALEMTUZUMAB AND CHLORAMBUCIL FOR CHRONIC LYMPHOCYTIC LEUKEMIA IN A TREATMENT-NAIVE POPULATION

 

Malin J1, Kongnakorn T2, Sterchele J3, Salvador C3, Getsios D4, Mwamburi M2
1David Geffen School of Medicine at UCLA, Los Angeles, CA, USA, 2United Biosource Corporation, Lexington, MA, USA, 3Cephalon, Frazer, PA, USA, 4United BioSource Corporation, Halifax, NS, Canada

PCN94

COST-MINIMIZATION ANALYSIS OF BIOPSY-BASED RISK STRATIFICATION TOOLS IN INTERMEDIATE-RISK PROSTATE CANCER PATIENTS

 

Zubek VB, Khan F
Aureon Laboratories, Inc., Yonkers, NY, USA

PCN95

COST-EFFECTIVENESS OF SEROTONIN-TYPE 3 RECEPTOR ANTAGONISTS FOR CHEMOTHERAPY-INDUCED EMESIS IN NON SMALL CELL LUNG CANCER PATIENTS RECEIVING CISPLATIN-BASED CHEMOTHERAPY

 

Colayco DC, Hay J
University of Southern California, Los Angeles, CA, USA

PCN96

A TRIAL-BASED ASSESSMENT OF THE COST-UTILITY OF BEVACIZUMAB AND CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

 

Goulart B1, Ramsey S2
1Pharmaceutical Outcomes Research and Policy Program, Seattle, WA, USA, 2Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA

PCN97

ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) CETUXIMAB TREATMENT DECISION MODEL: CHEMOTHERAPY+CETUXIMAB VS. CETUXIMAB TREAT-TO-RASH STRATEGY VS. CHEMOTHERAPY ONLY IN FIRST-LINE TREATMENT OF STAGE IIIB/IV NSCLC

 

Roth J1, Carlson J2
1University of Washington: Pharmaceutical Outcomes Research & Policy Program, Seattle, WA, USA, 2University of Washington, Seattle, WA, USA

PCN98

COST-EFFECTIVENESS OF ADJUVANT THERAPY WITH TRASTUZUMAB IN THE TREATMENT OF EARLY BREAST CANCER (EBC) IN ROMANIA

 

Grecea D1, Baculea S2, Radu PC3, Pana B3, Szkultecka-Debek M4
1Oncology Institute “Prof.Dr.Ion Chiricuta”, Cluj-Napoca, Romania, 2Roche Romania, Bucharest, Romania, 3Panmedica SRL, Craiova, Dolj, Romania, 4Roche Polska Sp. z o.o., Warszaw, Poland

PCN99

ECONOMIC EVALUATION OF DASATINIB FOR THE TREATMENT OF CHRONIC MYELOGENOUS LEUKAEMIA IN PATIENTS RESISTANT TO IMATINIB IN COLOMBIA AND VENEZUELA

 

Valencia Zapata JE1, Orozco G JJ1, Ribon GG2, Guerrero F2, Aiello EC3
1Universidad CES Medellín, Medellín, Colombia, 2Bristol-Myers Squibb, Bogotá, -, Colombia, 3Bristol-Myers Squibb, Buenos Aires, -, Argentina

PCN100

SIMILARITIES AND DIFFERENCES IN TREATMENT PATTERNS AND RESOURCE UTILISATION FOR MULTIPLE MYELOMA: A COMPARISON BETWEEN 4 NORDIC COUNTRIES

 

Persson S1, Ghatnekar O1, Liwing J2, Aschan J2, Mellqvist UH3
1The Swedish Institute for Health Economics, Lund, Sweden, 2Janssen-Cilag AB, Sollentuna, Sweden, 3Department of Hematology, Gothenburg, Sweden

PCN101

INPATIENT RESOURCE UTILIZATION IN BRONCHIAL AND LUNG CANCER: ANALYSIS OF 2007 HEALTHCARE UTILIZATION AND PROJECT (HCUP) DATA

 

Patel B1, Kamal KM1, Atreja N2
1Duquesne University, Pittsburgh, PA, USA, 2Duquesne university, pittsburgh, PA, USA

CANCER Patient-Reported Outcomes Studies

PCN102

EFFECTS OF VA ONCWATCH INTERVENTION ON COLORECTAL CANCER SCREENING ADHERENCE

 

Bian J1, Fisher D2, Lipscomb J3, Ribeiro M1, Byrd-Sellers J1
1Atlanta VAMC, Decatur, GA, USA, 2Duke University, Durham, NC, USA, 3Emory University, Rollins School of Public Health, Atlanta, GA, USA

PCN103

A REVIEW AND META-ANALYSIS OF COLORECTAL CANCER UTILITIES

 

Djalalov S1, Hoch J2, Tomlinson G3
1CRICH, Toronto, ON, Canada, 2Cancer Care Ontario, Toronto, ON, Canada, 3Toronto General Research Institute, Toronto, ON, Canada

PCN104

ESTIMATION AND COMPARISON OF EQ-5D HEALTH STATES' UTILITY WEIGHTS FOR PNEUMOCCOCAL AND HUMAN PAPILLOMAVIRUS DISEASES IN ARGENTINA, CHILE AND THE UNITED KINGDOM

 

Galante J1, Augustovski F1, Colantonio L1, Bardach A1, Garcia Marti S1, Caporale J1, Kind P2
1Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina, 2University of York, York, UK

PCN105

PATIENT PREFERENCE-BASED UTILITY WEIGHTS FROM THE FUNCTIONAL ASSESSMENT OF CANCER THERAPY-GENERAL (FACT-G) IN WOMEN WITH HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER RECEIVING LETROZOLE PLUS LAPATINIB OR LETROZOLE ALONE

 

Delea TE1, Sofrygin O1, Amonkar M2
1PAI (Policy Analysis Inc.), Brookline, MA, USA, 2GlaxoSmithKline, Philadelphia, PA, USA

PCN106

IMPACT OF AN INDIVIDUAL'S LOCUS OF CONTROL ON UTILITY VALUES FOR HEAD AND NECK CANCER HEALTH STATES

 

Levy AR1, Szabo S1, Johnston K1, Dobson RL1, Donato BM2
1Oxford Outcomes Ltd, Vancouver, BC, Canada, 2Bristol-Myers Squibb Co, Wallingford, CT, USA

PCN107

EVALUATION OF QUALITY OF LIFE FOR ANTI-CANCER TREATMENT AMONGST KOREAN METASTATIC BREAST CANCER PATIENTS: A MULTICENTER, CROSS-SECTIONAL STUDY

 

Lee JY1, Ko SK1, Kim EJ2
1Pfizer Pharmaceuticals Korea Limited, Seoul, South Korea, 2Graduate School of Public Health, Seoul National University, Seoul, South Korea

PCN108

PSYCHOMETRIC VALIDATION OF A PATIENT QUESTIONNAIRE EVALUATING SATISFACTION WITH A DARBEPOETIN ALPHA PRE-FILLED DEVICE FOR SELF-INJECTION (ARANESP®SURECLICKTMDEVICE), AND A HOME-SERVICE (2CARE®SERVICE) IN CHEMOTHERAPY-INDUCED ANAEMIC CANCER PATIENTS

 

de Jong FA1, Viala-Danten M2, van Herwaarden RH1, Poppe KA1, van Haaster CM1, Meunier J2, Rijnierse JJ1
1Amgen BV, Breda, The Netherlands, 2Mapi Values, Lyon, France

PCN109

DEVELOPMENT OF THE PATIENT-REPORTED VERSION OF THE COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS (PRO-CTCAE)

 

Basch E1, Reeve B2, Cleeland C3, Sloan J4, Mendoza T3, Abernethy A5, Bruner D6, Hay J1, Atkinson T1, Sit L1, Minasian L2, O'Mara A2, Burke L7, Schrag D8
1Memorial Sloan-Kettering Cancer Center, New York, NY, USA, 2National Cancer Institute, Bethesda, MD, USA, 3U.T.M.D. Anderson Cancer Center, Houston, TX, USA, 4Mayo Clinic, Rochester, MN, USA, 5Duke University, Durham, NC, USA, 6University of Pennsylvania, Philadelphia, PA, USA, 7Food and Drug Administration, Silver Spring, MD, USA, 8Dana-Farber Cancer Institute, Boston, MA, USA

PCN110

HOW MUCH DO PATIENTS WITH RENAL CELL CARCINOMA (RCC) VALUE PROGRESSION FREE SURVIVAL IN MEDICAL DECISION MAKING? - RESULTS FROM A BENEFIT-RISK CONJOINT STUDY

 

Hauber AB1, Mohamed AF1, Johnson FR1, Neary MP2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Novartis Pharmaceuticals, Collegeville, PA, USA

PCN111

PRO LABELLING CLAIMS IN ANTINEOPLASTIC AGENTS

 

Caron M, Emery MP
MAPI Research Trust, Lyon, France

PCN112

LITERATURE REVIEW AND PRODUCT LABEL CLAIM REVIEW FOR THE DEVELOPMENT OF A PATIENT-REPORTED OUTCOME RESEARCH STRATEGY FOR CANCER-RELATED ANEMIA

 

Hackshaw MD, Brown J
Eli Lilly and Company, Indianapolis, IN, USA

PCN113

HEALTH RELATED QUALITY OF LIFE, FEAR OF RECURRENCE, IMPACT OF EVENTS, ILLNESS INTRUSIVENESS AND PSYHOLOGICAL DISTRESS IN NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS

 

Sansgiry S1, Lerner SP2, Amiel GE2, Mei M1, Latini DM1
1Baylor College of Medicine; Health Services Research & Development Center of Excellence, Michael E. DeBakey VA Medical Center, Houston, TX, USA, 2Baylor College of Medicine, Houston, TX, USA

PCN114

EXPLORING THE BURDEN OF ILLNESS ON NEWLY DIAGNOSED ESOPHAGEAL CANCER PATIENTS IN TAIWAN –PRELIMINARY ANALYSIS

 

Lin HW, Ku CH, Lee RF, Shih TP, Liu YY, Lin CY
China Medical University, Taichung, Taiwan

PCN115

HEAD-TO-HEAD COMPARISONS OF QUALITY OF LIFE INSTRUMENTS FOR YOUNG ADULT SURVIVORS OF CHILDHOOD AND ADOLESCENT CANCER

 

Huang IC1, Quinn G2, Shenkman E1, Shearer P1
1University of Florida, Gainesville, FL, USA, 2H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

PCN116

PILOT STUDY FOR EVULATION OF OUTCOMES OF BREAST CANCER WITH SPECIAL FOCUS ON ECONOMIC IMPACT AND QUALITY OF LIFE

 

Nagappa AN, Punnackal DA, Udupa N, Vadhiraja BM
Manipal University, Manipal, India

PCN117

QUALITY OF LIFE SCALE FOR PATIENTS WITH HAND-FOOT SYNDROME : FIRST RESULTS

 

Sibaud V1, Rahhali N2, Charles T3
1Institut Claudius Regaud, Toulouse, France, 2PFSA, Boulogne , France, 3CREES PFSA, Boulogne, France

PCN118

USING DISCRETE CHOICE EXPERIMENTS TO ESTIMATE THE MARGINAL WILLINGNESS TO PAY OF INSURANCE PREMIUM FOR STOMACH CANCER TREATMENT IN KOREA

 

Jo C, Cho DH
Hallym University, Chuncheon, South Korea

PCN119

USING DISCRETE CHOICE EXPERIMENTS TO ESTIMATE THE WILLINGNESS TO PAY FOR CANCER TREATMENT IN KOREA: A GENERAL POPULATION STUDY

 

Jo C
Hallym University, Chuncheon, South Korea

PCN120

USING DISCRETE CHOICE EXPERIMENTS TO ESTIMATE THE MARGINAL WILLINGNESS TO PAY OF INSURANCE PREMIUM FOR LUNG CANCER TREATMENT IN KOREA

 

Jo C
Hallym University, Chuncheon, South Korea

PCN121

USING DISCRETE CHOICE EXPERIMENTS TO ESTIMATE THE MARGINAL WILLINGNESS TO PAY OF INSURANCE PREMIUM FOR LIVER CANCER TREATMENT IN KOREA

 

Jo C, Cho DH
Hallym University, Chuncheon, South Korea

CANCER Health Care Use & Policy Studies

PCN122

HPV VACCINE COVERAGE AND ADOPTION ACROSS THE UNITED STATES

 

Doyle J, Baumgartner J, Bell J
Quintiles Global Consulting, Hawthorne, NY, USA

PCN123

PREVALENCE AND CORRELATES OF HUMAN PAPILLOMAVIRUS VACCINATION IN ADOLESCENT GIRLS: RESULTS FROM NATIONAL SURVEY OF CHILDRENS HEALTH

 

Palli SR, Mehta S, Chatterjee S, Aparasu RR
University of Houston, Houston, TX, USA

PCN124

IDEAL VIAL SIZE FOR BORTEZOMIB: REAL WORLD DATA ON WASTE AND COST REDUCTION IN MULTIPLE MYELOMA (MM)

 

Castro APC, Alves AFF, Clark LGO, Santos FS, Clark O, Engel T, Pegoretti B
Evidencias, Campinas, Brazil

PCN125

NUMBER OF DOCETAXEL TREATMENT CYCLES AND OVERALL SURVIVAL FOR METASTATIC PROSTATE CANCER - RESULTS FROM A US LOCAL COMMUNICTY PRACTICE

 

Zhao L1, Seal B2, Tangirala M3, Sullivan SD4, Christiansen NP5
1eTeam. Inc, South Plainfield, NJ, USA, 2Sanofi-Aventis Pharmaceuticals, Bridgewater, NJ, USA, 3Smith Hanley Consulting Group LLC, Lake Mary, FL, USA, 4University of Washington, Seattle, WA, USA, 5Medical University of South Carolina, Charleston, SC, USA

PCN126

INEQUALITY OF FORMULARY COVERAGE OF COLORECTAL CANCER DRUGS AMONG TAIWAN'S NATIONAL HEALTH INSURANCE HOSPITALS

 

Huang WF1, Hsieh CF1, Cheng CW2, Cheng SH2
1Institute of Health & Welfare Policy, National Yang-Ming University, Taipei, Taiwan, 2Institute of Health Policy & Management, National Taiwan University, Taipei, Taiwan

PCN127

EFFECT OF ACCESS TO CANCER CARE ON AGE-SPECIFIC UTILIZATION OF CHEMOTHERAPY AMONG ELDERLY WOMEN WITH METASTATIC BREAST CANCER

 

Wan S1, Brooks J2, Chrischilles EA3, Thomas A4, Polgreen LA2, Sorofman BA2
1University of Iowa College of Pharmacy, Iowa City, IA, USA, 2Univ of Iowa College of Pharmacy, Iowa City, IA, USA, 3University of Iowa College of Public Health, Iowa City, IA, USA, 4University of Iowa Carver College of Medicine, Iowa City, IA, USA

PCN128

SOCIAL DISPARITIES ACROSS THE CONTINUUM OF LUNG CANCER: A SYSTEMATIC REVIEW OF THE LITERATURE

 

Nadpara P1, Madhavan S1, Tworek C2
1West Virginia University, Morgantown, WV, USA, 2West Virginia University School of Pharmacy, Morgantown, WV, USA

PCN129

RACIAL DISPARITIES ASSOCIATED WITH TREATMENT AND SURVIVAL IN ELDERLY PATIENTS WITH EARLY STAGE OPERABLE BREAST CANCER

 

Sail K, Franzini L, Du XL, Lairson D
University of Texas School of Public Health, Houston, TX, USA

PCN130

WITHDRAWN

 

 

PCN131

THE COST OF TREATING LUNG CANCER IN THE UNITED STATES: AN ANALYSIS OF THE MEDICAL EXPENDITURE PANEL SURVEY

 

Nadpara P1, Tworek C2, Madhavan S1
1West Virginia University, Morgantown, WV, USA, 2West Virginia University School of Pharmacy, Morgantown, WV, USA

PCN132

COST OF BREAST AND CERVICAL CANCER TREATMENT AND FOLLOW-UP CARE IN MEDICAID BENEFICARIES: IMPLICATIONS FOR STATE PROGRAMS PROVIDING COVERAGE FOR LOW-INCOME WOMEN

 

Ekwueme DU1, Subramanian S2, Trogdon J3, Gardner JG4
1Center for Disease Control and Prevention, Atlanta, GA, USA, 2RTI International, Waltham, MA, USA, 3RTI International, Research Triangle Park, NC, USA, 4CDC, Atlanta, GA, USA

PCN133

A SUCCESSFUL ADOPTION OF PERSONALIZED MEDICINE: EXAMPLE OF KRAS MUTATIONAL ANALYSIS

 

Wang G, Van Bebber S, Phillips K
University of California, San Francisco, San Francisco, CA, USA

PCN134

THE ECONOMIC IMPACT OF CONTOUR VERSUS HAND SEWN SUTURE AND OTHER MECHANICAL STAPLES IN LOW ANTERIOR RESECTIONS IN COLON RECTAL CANCER SURGERY: INTERIM RESULTS USING REAL WORLD DATA FROM PREMIER'S HOSPITAL DATABASE

 

Nasciben V1, Rupprecht F2, Moore M3, Gunnarsson C4
1Johnson & Johnson, Sao Paulo-SP, Brazil, 2Ethicon-Endo Surgery, Inc., Cincinnati, OH, USA, 3Ethicon Endo-Surgery, Cincinnati, OH, USA, 4S2 Statistical Solutions Inc, Cincinnati, OH, USA

PCN135

CONTROLLING THE COST OF CARE OF BREAST CANCER PATIENTS IN GERMANY USING CLINICAL PATHWAYS

 

Bosch C1, Vogel S2, Schrappe M3, Grischke E-M4, Seyfarth-Metzger I4, Breitscheidel L1
1Kendle GmbH, Munich, Germany, 2Local Health Authority, Munich, Germany, 3Institute for Patient Safety, Bonn, Germany, 4State Hospital Schwabing, Munich, Germany

PCN136

THE IMPACT OF PROSTATE CANCER AMONG CAUCASIAN AND AFRICAN AMERICANS IN A HOSPITALIZED SETTING

 

Atkins E, Halverson J
West Virginia University, Morgantown, WV, USA

PCN137

CHARACTERISTICS OF PATIENTS AND PREDICTORS OF IN-HOSPITAL MORTALITY AFTER HOSPITALIZATION FOR LUNG CANCER IN WEST VIRGINIA

 

Nadpara P1, Tworek C2, Madhavan S1
1West Virginia University, Morgantown, WV, USA, 2West Virginia University School of Pharmacy, Morgantown, WV, USA

PCN138

THE FINANCIAL EFFECT OF THE INTRODUCTION OF PERFORMANCE-VOLUME LIMIT (PVL) ON THE HUNGARIAN ONCOLOGY CARE

 

Boncz I1, Donka-Verebes É2, Oberfrank F3
1University of Pécs, Pécs, Hungary, 2Intergra Consulting Ltd., Budapest, Hungary, 3Institute of Experimental Medicine, Budapest, Hungary

PCN139

OPTIMISING MARKET ACCESS FOR ONCOLOGY DRUGS IN BRAZIL & CHINA

 

Dummett H, Shankland B
Double Helix Consulting, London, UK

PCN140

INFLUENCE OF HEALTH TECHNOLOGY ASSESSMENTS ON UTILIZATION OF BEVACIZUMAB IN EUROPE

 

Toumi M1, Misset JL2, Maman K3, Krukowski L4, Aballea S5, Lamure M6
1University Claude Bernard Lyon 1, LYON Cedex 08, France, 2Hopital Saint Louis, Paris, France, 3University Claude Bernard Lyon 1, Lyon Cedex 08, France, 4Synovate, London, England, 5CREATIV-CEUTICAL, Paris, France, 6University Claude Bernard Lyon 1, Paris, France

PCN141

USING A DISEASE MANAGEMENT APPROACH IN A HEALTH TECHNOLOGY ASSESSMENT: A CASE STUDY

 

Walker JB1, Stafinski T1, McCabe C2, Menon D1
1University of Alberta, Edmonton, AB, Canada, 2University of Leeds, Leeds, UK

PCN142

EVALUATING COMPARATIVE EFFECTIVENESS RESEARCH FOR ONCOLOGY IN THE US: AN ANALYSIS BASED ON LESSONS FROM HEALTH TECHNOLOGY ASSESSMENTS IN EUROPE

 

Patel P1, Roberts S2, Sparrowhawk K1, Ng-Haing J1
1PriceSpective LLC, London, UK, 2PriceSpective, BlueBell, PA, USA

PCN143

COST-EFFECTIVENESS OBSERVATIONS AND ONCOLOGY DRUG REIMBURSEMENT RECOMMENDATIONS IN CANADA BY THE JOINT ONCOLOGY DRUG REVIEW

 

Ciapanna CC1, Yunger S1, Shum D1, Milliken D1, Longo CJ2, Aissa F1
1Hoffmann-La Roche Limited, Mississauga, ON, Canada, 2McMaster University, Hamilton, ON, Canada

PCN144

COMPARITIVE KNOWLEDGE OF BREAST SELF EXAMINATION IN MIDWIFERY AND NURSING STUDENTS IN ISLAMIC AZAD UNIVERSITY KARAJ BRANCH

 

Ashkvary P
Islamic Azad University Of Iran Karaj Branch, kARAJ, Tehran, Iran

PCN145

A COMPARISON OF PHYSICIAN AND PATIENT DECISION MAKING FOR FIRST VERSUS SECOND OPINIONS AMONG MEN WITH LOCAL STAGE PROSTATE CANCER

 

Ramsey S1, Zeliadt SB2, Blough DK3, Fedorenko CR1, Moinpour CM1, Hall IJH4, Lee Smith J4, Ekwueme DU5, Fairweather ME1, Thompson Jr. IM6, Keane TE7, Penson D8
1Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA, 2VA Puget Sound Health Care System, Seattle, WA, USA, 3University of Washington, Seattle, WA, USA, 4Center for Disease Control and Prevention, Atlanta, GA, USA, 5Center for Disease Control and Prevention, Snellville, GA, USA, 6University of Texas Health Science Center, San Antonio, TX, USA, 7Medical University of South Carolina Medical Center, Charleston, SC, USA, 8Vanderbilt University Medical Center, Nashville, TN, USA

PCN146

REAL WORLD DATA ON MULTIPLE MYELOMA (MM) TREATMENT IN BRAZIL: GUIDANCE FOR THE PRIVATE HEALTHCARE SYSTEM (PHS)

 

Alves AFF, Castro APC, Clark LGO, Santos FS, Clark O, Engel T, Pegoretti B
Evidencias, Campinas, Brazil

PCN147

CHARACTERISTICS OF POSTMENOPAUSAL WOMEN INITIATING RALOXIFENE BEFORE AND AFTER APPROVAL OF INVASIVE BREAST CANCER RISK REDUCTION INDICATIONS

 

Foster S1, McQuarrie N2, Coleman A1, Whangbo A2, Miller LA1, Bhujabal S2, Gilra N2
1Eli Lilly and Company, Indianapolis, IN, USA, 2ZS Associates, New York, NY, USA

PCN148

YEAR ONE EVALUATION OF PARTICIPATION AND COMPLIANCE IN REGIONAL PAY FOR QUALITY (P4Q) ONCOLOGY PROGRAM

 

Fortner B1, Wong W2, Olson T3, Scott J4
1P4 Healthcare LLC, Ellicott City , MD, USA, 2CareFirst BlueCross BlueShield, Baltimore, MD, USA, 3P4 Healthcare, Minneapolis, MN, USA, 4P4 Healthcare LLC, Ellicott City, MD, USA

PCN149

ELECTRONIC MEDICAL RECORDS : QUALITY CANCER CARE AND COST-EFFECTIVENESS

 

Colosia AD1, Peltz G2, Pohl G2, Liu E2, Kaye JA3, Khan S1
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Eli Lilly and Company, Indianapolis, IN, USA, 3RTI Health Solutions, Waltham, MA, USA

PCN150

TRENDS IN USAGE AND UPTAKE OF TARGETED CANCER THERAPIES VERSUS CHEMOTHERAPIES

 

Aggarwal S1, Stevens CA(2
1PAREXEL Consulting, Bethesda, MD, USA, 2PAREXEL Consulting, Waltham, MA, USA

PCN151

CLINICAL AND SOCIO-DEMOGRAPHIC DETERMINANTS OF PRIMARY PROPHYLACTIC G-CSF USE IN ELDERLY BREAST CANCER MEDICARE BENEFICIARIES RECEIVING CHEMOTHERAPY

 

Rajan SS1, Lyman G2
1University of Houston, Houston, TX, USA, 2Duke University, Durham, NC, USA

PCN152

TREATMENT PATTERNS IN ADULT PATIENTS WITH METASTATIC RENAL CELL CARCINOMA IN THE UNITED STATES

 

Gao SK1, Boer R2, Oglesby A3, Lalla A2, Yu HT2, Langeberg WJ1, Calimlim B2, Borker R1
1Amgen, Inc., Thousand Oaks, CA, USA, 2Cerner LifeSciences, Beverly Hills, CA, USA, 3Amgen, Thousand Oaks, CA, USA

PCN153

TREATMENT PATTERNS OF MEXICAN ONCOLOGISTS IN FIVE DIFFERENT MALIGNANCIES: A SURVEY

 

Tenorio-Téllez LMC1, Vargas-Valencia J2, Martínez-Fonseca J2, Sotelo-Guzmán M2, Mould-Quevedo JF3
1Instituto Nacional de Cancerología, Mexico City, Mexico, Mexico, 2Econopharma Consulting S. A. de C. V., Mexico City, Mexico, Mexico, 3Pfizer S.A. de C.V., México City, Mexico

PCN154

COLORECTAL CANCER HOSPITAL ADMISSIONS IN WEST VIRGINIA FROM 2003 TO 2007

 

Shah N, Halverson J
West Virginia University, Morgantown, WV, USA

PCN155

TREATMENT PATTERN OF METASTATIC TRIPLE NEGATIVE BREAST CANCER IN COMMUNITY PRACTICE

 

Christiansen NP1, Chen L2, Chung H3, Zhao L4, Sullivan SD5
1Medical University of South Carolina, Charleston, SC, USA, 2Sanofi-Aventis, Bridgewater, NJ, USA, 3Rutgers University, Piscataway, NJ, USA, 4eTeam. Inc, South Plainfield, NJ, USA, 5University of Washington, Pharmaceutical Outcomes Research and Policy Program, Seattle, WA, USA

HE3

CAN INNOVATION BE REWARDED WITH THE APPLICATION OF RIGID COST-EFFECTIVENESS THRESHOLDS? THE HER2+VE BREAST CANCER CASE STUDY

 

Ray J, Cirrincione A
F. Hoffmann-La Roche Ltd., Basel, Switzerland

CANCER Conceptual Papers & Research on Methods

PCN156

IMPROVING ASCERTAINMENT OF VITAL STATUS USING SOCIAL SECURITY DEATH MASTER FILE (SSDMF) AND THE NATIONAL DEATH INDEX (NDI)

 

Stevinson K1, Ma L2, Moore KR3, Burke T4
1Rutgers University, Piscataway, NJ, USA, 2Global Outcomes Research, Merck & Co., Inc., West Point, PA, USA, 3i3 Pharma Informatics, Harrisburg, PA, USA, 4Merck & Co., Inc., Whitehouse Station, NJ, USA

PCN157

METHODOLOGIC ISSUES OF IDENTIFYING FEBRILE NEUTROPENIA PATIENTS USING MEDICAL CLAIM DATA

 

Michels SL1, Barron R2
1United BioSource Corporation, Lexington, MA, USA, 2Amgen, Thousand Oaks, CA, USA

PCN158

A METHOD TO INCREASE SAMPLE SIZE BY REMOVING THE CONTINUOUS ENROLLMENT REQUIREMENT

 

Baser O1, Yuce H2
1STATinMED Research / University of Michigan, Ann Arbor, MI, USA, 2STATinMED Research / City University of New York, Ann Arbor, MI, USA

PCN159

HFS 14: A SPECIFIC QUALITY OF LIFE SCALE FOR PATIENTS WITH HAND-FOOT SYNDROME

 

Sibaud V1, Dalenc F1, Rahhali N2, Charles T2
1Institut Claudius Regaud,, Toulouse, , France, 2CREES PFSA, Boulogne , France

PCN160

PATIENT-REPORTED OUTCOMES SUPPORTING ONCOLOGY PRODUCT LABELING CLAIMS: TRENDS AND CHALLENGES

 

Hao Y
Mapi Values, Boston, MA, USA

POSTER PRESENTATIONS SESSION I
SET-UP: Monday, May 17, 2010 – 7:30AM – 8:00AM
POSTER DISPLAY HOURS: Monday, May 17, 2010 – 8:00AM – 8:30PM
POSTER AUTHOR DISCUSSION HOUR: Monday, May 17, 20106:30PM – 7:30PM
DISMANTLE: Monday, May 17, 2010 – 8:30PM – 9:00PM

DIABETES/ENDOCRINE DISORDERS Clinical Outcomes Studies

PDB1

ASSOCIATION BETWEEN GLYCOSYLATED HEMOGLOBIN AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A NESTED CASE-CONTROL STUDY

 

Colayco D1, Cheetham CT2, Niu F2, McCombs J1
1USC School of Pharmacy, Los Angeles, CA, USA, 2Kaiser Permanente, Downey, CA, USA

PDB2

THE IMPACT OF ORAL ANTIDIABETICS ON WEIGHT IN THE ELDERLY WITH TYPE 2 DIABETES MELLITUS IN THE AMBULATORY SETTING

 

Tasic D, Brixner D, Goodman M
Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT, USA

PDB3

WITHDRAWN

 

 

PDB4

PREVALENCE OF RENAL INSUFFICIENCY IN A COMMERICALLY-INSURED POPULATION WITH TYPE 2 DIABETES MELLITUS ENROLLED IN A LARGE, US NATIONAL HEALTH PLAN

 

Burke JP1, Sander S2, Parker M3, Moran HJ4, Thayer S5
1i3 Innovus, Eden Prairie, MN, USA, 2Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA, 3Boehringer-Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, 4i3 Global, Cary, NC, USA, 5i3 Innovus, San Francisco, CA, USA

PDB5

GLYCAEMIC CONTROL AND INSULIN UTILIZATION IN UK PATIENTS WITH TYPE 2 DIABETES INITIATED ON EITHER BIPHASIC INSULIN ASPART 30 OR BIPHASIC HUMAN INSULIN 30

 

Fakhoury W1, Richter H2, Christensen T3, Thomsen TL4, Irwin D5, Anderson P1
1IMS Health, London, UK, 2IMS Health GmbH & Co. OHG, Frankfurt am Main, Germany, 3Novo Nordisk, Virum, Denmark, 4Novo Nordisk A/S, Virum, Denmark, 5University of North Carolina – Chapel Hill, Chapel Hill, NC, USA

PDB6

RELATIVE EFFECTIVENESS MANAGEMENT OF TYPE II DIABETES IN EUROPE: CAN THE AGENCIES' DEMANDS BE MET?

 

Hemels M1, Jensen RCØ1, Toumi M2, Adalsteinsson E3
1Novo Nordisk A/S, Bagsværd, Denmark, 2University Claude Bernard Lyon I, Villeurbanne Cedex, France, 3Novo Nordisk A/S, Soeborg, Denmark

PDB7

GLYCAEMIC CONTROL AND INSULIN UTILISATION IN PATIENTS WITH TYPE 2 DIABETES INITIATED ON A LONG-ACTING INSULIN ANALOGUE IN A DUTCH REAL-LIFE SETTING

 

Heintjes E1, Thomsen TL2, Penning FJA1, Christensen T2, Herings RMC3
1PHARMO Institute, Utrecht, The Netherlands, 2Novo Nordisk A/S, Virum, Denmark, 3PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands

PDB8

FEWER TREATMENT CHANGES WITH PREMIXED INSULIN ANALOGUES COMPARED TO PREMIXED HUMAN INSULIN – A REAL-LIFE TREATMENT PATTERN ANALYSIS OF PATIENTS WITH TYPE 2 DIABETES IN THE NETHERLANDS

 

Thomsen TL1, Heintjes E2, Penning FJA2, Christensen T1, Herings RMC3
1Novo Nordisk A/S, Virum, Denmark, 2PHARMO Institute, Utrecht, The Netherlands, 3PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands

PDB9

DIABETES RISK ASSESSMENT - APPLICATION AND VALIDATION OF A DIABETES SCREENING SCORE APPLIED TO THE NATIONAL HEALTH AND WELLNESS SURVEY

 

Langley PC1, Bang H2, Annunziata K3, Gross H3
1University of Minnesota, Minneapolis, MN, USA, 2Cornell University, New York, NY, USA, 3KantarHealth, Princeton, NJ, USA

PDB10

SURVIVAL AS A FUNCTION OF HBA1C IN PEOPLE WITH TYPE 2 DIABETES: A RETROSPECTIVE COHORT STUDY

 

Poole CD1, Evans LM2, Peters JR3, Currie CJ4
1Pharmatelligence, Cardiff, UK, 2University Hospital of Wales, Cardiff, Vale of Glamorga, UK, 3University Hospital of Wales, Cardiff, South Glamorgan, UK, 4Cardiff University, Cardiff, Wales, UK

PDB11

RISK OF CARDIOVASCULAR EVENTS IN PATIENTS WITH DIABETES TREATED WITH EXENATIDE OR THIAZOLIDINEDIONES: A RETROSPECTIVE ANALYSIS OF THE PHARMETRICS DATABASE

 

Best JH1, Pelletier E2, Hoogwerf BJ3, Herman WH4, DeYoung MB1, Smith DB2, Yushmanova I1, Hussein M5
1Amylin Pharmaceuticals, Inc., San Diego, CA, USA, 2IMS Health, Watertown, MA, USA, 3Eli Lilly and Company, Indianapolis, IN, USA, 4University of Chicago, Ann Arbor, MI, USA, 5IMS Health, Falls Church, VA, USA

PDB12

PREDICTORS OF STATIN USE AMONG OVERWEIGHT AND OBESE ADULTS IN AMBULATORY CARE SETTING IN THE UNITED STATES

 

Patel A, Bhattacharjee S, Yang M, Tseng WW, Abughosh S
University of Houston, Houston, TX, USA

DIABETES/ENDOCRINE DISORDERS Cost Studies

PDB13

BUDGET IMPACT ANALYSIS OF SAXAGLIPTIN FOR THE TREATMENT OF DIABETES MELLITUS TYPE 2 (T2D) PATIENTS IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM

 

Barbosa E1, Ribeiro E2, Asano E1, Nita M1, Rached R1, Mantilla P1, Pimentel A3, Donato BM4, Rahal E1
1Bristol-Myers Squibb S/A, São Paulo, São Paulo, Brazil, 2University Hospital of the University of São Paulo, São Paulo, São Paulo, Brazil, 3AstraZeneca do Brasil Ltda., Cotia, São Paulo, Brazil, 4Bristol-Myers Squibb Co, Wallingford, CT, USA

PDB14

BUDGET IMPACT ANALYSIS OF THE INTRODUCTION OF SAXAGLIPTIN IN THE TREATMENT OF TYPE 2 DIABETES IN ARGENTINA

 

Elgart J1, Caporale J1, Gagliardino JJ1, Waschbusch M2, Aiello EC2, Jotimliansky L2
1National University of La Plata, La Plata, Buenos Aires, Argentina, 2Bristol-Myers Squibb, Buenos Aires, Argentina

PDB15

ECONOMIC OUTCOMES OF THREE INSULIN THERAPY PROTOCOLS IMPLEMENTED IN A SURGICAL INTENSIVE CARE UNIT

 

Klinski AA1, Pandey G2, Sansgiry S1, Mallow-Corbett S3, Todd SR4
1University of Houston, Houston, TX, USA, 2Walgreens Pharmacy, Visalia, CA, USA, 3University of Virginia Health System, Charlottesville, VA, USA, 4The Methodist Hospital, Houston, TX, USA

PDB16

IMPACT OF NOVOLOG EXTENDED DRUG STABILITY ON HEALTH PLAN EXPENDITURES FOR INSULIN AND SUPPLIES IN PUMP USERS

 

Bazalo G1, Weiss RC2, Bouchard J3, Aagren M4
1Managed Solutions, LLC, Conifer, CO, USA, 2Managed Solutions, LLC, Randolph, NJ, USA, 3Novo Nordisk, Plaistow, NH, USA, 4Novo Nordisk Inc, Princeton, NJ, USA

PDB17

THE HEALTHCARE COSTS OF LONG-ACTING INSULIN ANALOGS COMPARED WITH NPH INSULIN IN PATIENTS WITH TYPE 2 DIABETES USING A BASAL REGIMEN: A DANISH PERSPECTIVE

 

Gundgaard J1, Christensen T2, Thomsen TL2
1COWI, Kongens Lyngby, Denmark, 2Novo Nordisk A/S, Virum, Denmark

PDB18

COSTS OF DIABETES TREATMENT IN THE MEXICAN PRIVATE SECTOR

 

Juarez-Garcia A1, Anaya P2, Vargas-Valencia J3, Polanco AC2, Uc-Coyoc R1, Rangel S1, Donato BM4
1Bristol Myers Squibb, D.F., Mexico, 2AstraZeneca Mexico, Estado de México, Mexico, 3Econopharma Consulting S. A. de C. V., Mexico City, Mexico, Mexico, 4Bristol-Myers Squibb Co, Wallingford, CT, USA

PDB19

COMPLICATIONS OF TYPE II DIABETES AND THEIR COST

 

Khowaja S1, Khowaja LA2
1Aga Khan University, Karachi, Sindh, Pakistan, 2Aga Khan University, Karachi, Pakistan

PDB20

AN ANALYSIS OF DIFFERENCES IN COST QUARTILES FOR PATIENTS WITH TYPE 2 DIABETES IN A LARGE CLAIMS DATABASE WITH LINKED LABORATORY RESULTS

 

Borah B1, Nigam S2, Steinbuch M2, Neslusan C3
1Mayo Clinic, Rochester, MN, USA, 2Johnson & Johnson, New Brunswick, NJ, USA, 3Johnson & Johnson, Raritan, NJ, USA

PDB21

MEDICAL COST AND SETTLEMENT PATTERN STUDY ON DIABETES MELLITUS INSURANTS IN CHINA

 

Xiong X1, Lin J1, Xiong G2
1China Health Insurance Research Association, Beijing, China, 2Tongji Medical School of Huangzhong University of Socience and Technology, Wuhan, China

PDB22

HEALTH CARE COSTS AND RESOURCE UTILIZATION OF PATIENTS WITH TYPE 2 DIABETES MELLITUS WITHIN A NATIONAL US MANAGED CARE POPULATION

 

Burke JP1, Parker M2, Sander S3, Moran HJ4, Thayer S5
1i3 Innovus, Eden Prairie, MN, USA, 2Boehringer-Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, 3Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA, 4i3 Global, Cary, NC, USA, 5i3 Innovus, San Francisco, CA, USA

PDB23

RESOURCE CONSUMPTION AND COSTS OF CARE THE YEAR BEFORE AND AFTER INITIATION OF INSULIN THERAPY IN SWEDISH PATIENTS WITH TYPE 2 DIABETES

 

Pettersson B1, Lindgren P2, Ringborg A3, Martinell M4, Stalhammar J4
1MSD, SWEDEN, Sollentuna, Sweden, 2i3 Innovus, Stockholm, Sweden, 3I3 innovus and Karolinska University, Stockholm, Sweden, 4Department of Public Health and Caring Sciences, Uppsala, Sweden

PDB24

COST-EFFECTIVENESS OF ROUX-EN-Y GASTRIC BYPASS IN TYPE 2 DIABETES PATIONTS IN CANADA

 

Hashemi L, Minshall ME
Covidien, North Haven, CT, USA

PDB25

THE ECONOMIC IMPACT OF WEIGHT LOSS FOR PATIENTS WITH NEWLY DIAGNOSED TYPE 2 DIABETES MELLITUS (T2DM) IN THE US

 

Willis M1, Asseburg C2, Neslusan C3, He J3, Ingham M3
1IHE, Lund, Sweden, 2ESiOR, Kuopio, Finland, 3Johnson and Johnson Pharmaceutical Services L.L.C., Raritan, NJ, USA

PDB26

MODELLING COST EFFECTIVENESS OF BEHAVIOUR MODIFICATION PROGRAMMES AND EFFECTS ON MEDICATION: CASE STUDY OF EDUCATION PROGRAMMES IN DIABETES

 

Brennan A, Gillett M
University of Sheffield, SHEFFIELD, UK

PDB27

COST AND EFFECTIVENESS OF EDUCATIONAL STRATEGIES FOR THE CONTROL AND TREATMENT OF TYPE 2 DIABETES (DMT2) AND CARDIOVASCULAR RISK FACTORS (CVRF)

 

Caporale JE, Pfirter G, Elgart J, Gonzalez L, Rucci E, Lapertosa S, Villagra M, Gagliardino JJ
National University of La Plata, La Plata, Buenos Aires, Argentina

PDB28

COST-EFFECTIVENESS OF SOMASTATIN ANALOGUES FOR THE TREATMENT OF ACROMEGALY IN COLOMBIA

 

Alfonso R1, Izquierdo C2, Diaz-Sotelo OD2, Maestre K3, Zarate JP3
1University of Washington, Seattle, WA, USA, 2RANDOM Foundation, Bogota, DC, Colombia, 3Novartis A.G., Bogotá, DC, Colombia

PDB29

COST/EFFECTIVENESS STUDY OF THIAZOLIDINEDIONES IN DIABETIC MEDICATION~A TAIWANESE EMPIRICAL STUDY

 

Huang WF1, Tsai YW1, Hsiao FY2, Hsieh CF1, Yang CL1
1Institute of Health & Welfare Policy, National Yang-Ming University, Taipei, Taiwan, 2University of Maryland School of Pharmacy, Baltimore, MD, USA

PDB30

COST-EFFECTIVENESS ANALYSIS OF THE DIABETES MEDICATIONS IN MEDICARE WITH SAS

 

Wang X
University of Louisville, Louisville, KY, USA

PDB31

REDUCED LONG-TERM COSTS AND CARDIOVASCULAR COMPLICATIONS IN PATIENTS INITIATED ON RAPID-ACTING INSULIN ASPART COMPARED WITH HUMAN INSULIN

 

Pollock R1, Valentine W1, Thomsen TL2, Nishimura H3
1Ossian Health Economics and Communications, Basel, Switzerland, 2Novo Nordisk A/S, Virum, Denmark, 3Osaka Saiseikai Nakatsu Hospital, Osaka, Kansai, Japan

PDB32

ECONOMIC AND HEALTH CONSEQUENCES OF THE USE OF A DPP4 PLUS METPHORMINE SCHEME IN THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES IN MEXICO FROM THE PRIVATE PERSPECTIVE

 

Anaya P1, Juarez-Garcia A2, Vargas-Valencia J3, Uc-Coyoc R2, Donato BM4, Islas S5
1AstraZeneca, Naucalpan, Mexico, 2Bristol Myers Squibb, D.F., Mexico, 3Econopharma Consulting, D.F., Mexico, 4Bristol-Myers Squibb Co, Wallingford, CT, USA, 5Mexican Social Security Institute, D.F., Mexico

PDB33

ECONOMIC EVALUATION OF THREE FIRST-LINE MEDICATIONS IN PAINFUL DIABETIC PERIPHERAL NEUROPHATY IN MEXICO

 

Carlos F1, Ramirez J1, Galindo-Suarez RM2, Dueñas H2
1R A C SALUD CONSULTORES S.A. de C.V., México, D.F., Mexico, 2Eli Lilly de México,S.A. de C.V., Mexico City, Mexico

PDB34

A COST-MINIMIZATION ANALYSIS FOR TYPE 2 DIABETES WITH INSULIN GLARGINE COMPARED TO INSULIN DETERMIR IN A BASAL SUPPORTED ORAL THERAPY IN CHINA

 

Dong H
Zhejiang University, Hanzhou, China

PDB35

COST-EFFECTIVENESS ANALYSIS OF METFORMIN COMBINED WITH SAXAGLIPTIN VS. METFORMIN COMBINED WITH SULFONYLUREAS IN TYPE 2 DIABETES PATIENTS IN ARGENTINA

 

Elgart J1, Caporale J2, Gagliardino JJ1, Aiello EC3, Waschbusch M4, Jotimliansky L3
1National University of La Plata, La Plata, Buenos Aires, Argentina, 2National University of La Plata, La Plata, Prov. de Bs As., Argentina, 3Bristol-Myers Squibb, Buenos Aires, -, Argentina, 4Bristol-Myers Squibb, Buenos Aires, Argentina

PDB36

ASSESSING THE IMPACT OF PAINFUL DIABETIC PERIPHERAL NEUROPATHY (PDPN) OR POST-HERPETIC NEURALGIA (PHN) RELATED HEALTH IMPAIRMENT ON LOSS OF PRODUCTIVE TIME (LOPT)

 

Gu NY1, Bell C2, Botteman M1, Van Hout BA3
1Pharmerit North America, LLC, Bethesda, MD, USA, 2GlaxoSmithBell, Research Triangle Park, NC, USA, 3University of Sheffield, Sheffield, UK

PDB37

THE IMPACT OF DIABETES ON WORKPLACE ABSENTEEISM AND PRESENTEEISM: A COMPARISON OF CHINA AND JAPAN

 

Langley PC1, Stankus A2, Annunziata K2, Gross H2
1University of Minnesota, Minneapolis, MN, USA, 2KantarHealth, Princeton, NJ, USA

PDB38

THE IMPACT OF DIABETES ON WORKPLACE PRESENTEEISM: A CROSS NATIONAL STUDY IN THE EUROPEAN UNION

 

Langley PC1, Annunziata K2
1University of Minnesota, Minneapolis, MN, USA, 2KantarHealth, Princeton, NJ, USA

PDB39

WITHDRAWN

 

 

DIABETES/ENDOCRINE DISORDERS Patient-Reported Outcomes Studies

PDB40

WITHDRAWN

 

 

PDB41

BELIEFS AND EXPECTATIONS ABOUT DIABETES AND MEDICATION ADHERENCE IN PERSONS WITH TYPE 2 DIABETES

 

Iyer N, Thomas J
Purdue University, West Lafayette, IN, USA

PDB42

PATIENT COMPLIANCE TO EXTENDED-RELEASE VERSUS IMMEDIATE-RELEASE GLIPIZIDE FOR TYPE 2 DIABETES MELLITUS: A SYSTEMATIC REVIEW

 

Wang L, Li Y
West China Hospital, Sichuan University, Chengdu, China

PDB43

ADHERENCE AND PERSISTENCE AMONG TYPE II DIABETIC PATIENTS STARTING MONOTHERAPY ON ORAL HYPOGLYCEMIC AGENTS

 

Jariwala K1, Banahan III BF2, Yang Y2, Pace PF1
1University of Mississippi, Oxford, MS, USA, 2University of Mississippi, University, MS, USA

PDB44

A SYSTEMATIC REVIEW OF ADHERENCE, QUALITY OF LIFE AND MEDICAL COSTS IN FIXED-DOSE COMBINATION REGIMENS IN DIABETES

 

Hutchins V1, Krishnarajah G2, Fleurence R1
1United BioSource Corp., Bethesda, MD, USA, 2Bristol-Meyers Squibb, Plainboro, NJ, USA

PDB45

ASSOCIATION BETWEEN HEALTH INSURANCE PLAN TYPE AND MEDICATION POSSESSION RATIOS IN ADULT WORKING AGE PATIENTS WITH TYPE 2 DIABETES MELLITUS

 

Kirk JR1, Campbell C1, Fonseca V1, Zhao Y1, Olukotun AY2, Shi L1
1Tulane University, New Orleans, LA, USA, 2CarioVax, LLC, Princeton, NJ, USA

PDB46

ADHERENCE TO STATIN THERAPY AMONG THE DIABETES PATIENTS AT A SELF-INSURED MID-WESTERN UNIVERSITY IN THE UNITED STATES

 

Kumar J, Holiday-Goodman M, Pinto S, Amialchuk A
University of Toledo, Toledo, OH, USA

PDB47

IMPROVING OUTCOMES AND PRODUCTIVITY FOR EMPLOYEES WITH DIABETES

 

Pinto S1, Partha G1, Ferrell M1, Coehrs B2, Riepenhoff C2
1University of Toledo, Toledo, OH, USA, 2Pharmacy Counter, Toledo, OH, USA

PDB48

ASSESSING QUALITY OF LIFE IN SHORT STATURE YOUTH – THE QOLISSY PROJECT FOCUS GROUP AND COGNITIVE DEBRIEFING EXPERIENCE

 

Bullinger M1, Dellenmark Blom M2, Feigerlova E3, Herdman M4, Lunde C2, Mimoun E3, Pleil A5, Power M6, Quitmann J1, Rohenkohl A1, Sanz D4, Skoropadskaya A6, Wollmann H7, Chaplin J2
1Hamburg University, Hamburg, Germany, 2The Queen Silvia Children's Hospital, Göteborg, Sweden, 3Hôpital des enfants, Toulouse, France, 4Insight Consulting & Research S.L., Barcelona, Spain, 5Pfizer Incorporated, San Diego, CA, USA, 6University of Edinburgh, Edinburgh, UK, 7Pfizer, Ltd, Walton Oaks, UK

PDB49

AGE-SPECIFIC ORIGINALS: USING THE PEDIATRIC QUALITY OF LIFE™ (PEDSQL™) DIABETES MODULE TO STUDY SIMILARITIES AND DIFFERENCES IN TARGET LANGUAGES

 

Neewoor S1, Varni JW2
1MAPI Institute, Lyon, France, 2Texas A&M University, College Station, TX, USA

PDB50

THE IMPACT OF OBESITY AND QUALTY OF LIFE ON MEDICAL AND LOST PRODUCTIVITY COSTS IN DIABETIC PATIENTS

 

Suh DC1, Kim CM2, Kwon JW1, Jang SM3, McGuire M1, Qureshi Z1
1Rutgers University School of Pharmacy, Piscataway, NJ, USA, 2Catholic University School of Medicine, Seoul, South Korea, 3Health Insurance Review Agency, Seoul, South Korea

PDB51

THE IMPACT OF NON-SEVERE HYPOGLYCEMIC EPISODES ON WORK PRODUCTIVITY AND DIABETES MANAGEMENT: A FOUR COUNTRY PERSPECTIVE

 

Brod M1, Christensen T2, Lyager Thomsen T3, Bushnell D4
1The Brod Group, Mill Valley, CA, USA, 2Novo Nordisk A/S, Virum, Denmark, 3Novo Nordisk, Virum, Denmark, 4Health Research Associates, Inc., Mountlake Terrace, WA, USA

PDB52

ATTEMPTED WEIGHT LOSS OR REGULAR EXERCISE: IMPACT ON QUALITY OF LIFE AMONG ADULTS WITH AND WITHOUT TYPE 2 DIABETES MELLITUS

 

Green A1, Fox KM2, Grandy S3
1Midwestern Endocrinology, Overland Park, KS, USA, 2Strategic Healthcare Solutions, LLC, Monkton, MD, USA, 3AstraZeneca LP, Wilmington, DE, USA

PDB53

IMPACT OF HYPOGLYCAEMIA ON PATIENT REPORTED OUTCOMES: A SYSTEMATIC LITERATURE REVIEW

 

Krishnarajah G1, Pollack M2, Balar BA1, Wieffer H3, Zhang Y3, Modha R3
1Bristol Myers Squibb, Plainsboro, NJ, USA, 2Astrazenca, wilmington, DE, USA, 3HERON, London, UK

DIABETES/ENDOCRINE DISORDERS Health Care Use & Policy Studies

PDB54

CLINICAL AND ECONOMIC OUTCOMES OF A DIABETES MEDICATION MANAGEMENT PROGRAM

 

Kim Y1, Prasla K1, Rascati K2, Tabor T1, Juan J1, Godley PJ1
1Scott & White Health Plan, Temple, TX, USA, 2University of Texas, College of Pharmacy, Austin, TX, USA

PDB55

THE IMPACT OF DIABETIC NON- SEVERE HYPOGLYCEMIC EPISODES ON FUNCTIONING AND DIABETES MANAGMENT: A 4 COUNTRY PERSPECTIVE

 

Brod M1, Christensen T2, Lyager Thomsen T3, Bushnell D4
1The Brod Group, Mill Valley, CA, USA, 2Novo Nordisk A/S, Virum, Denmark, 3Novo Nordisk, Virum, Denmark, 4Health Research Associates, Inc., Mountlake Terrace, WA, USA

PDB56

RELATIONSHIP BETWEEN CARE FINANCING STRUCTURE AND DIABETES CARE ASSESSMENTS AMONG MEDICAID BENEFICIARIES WITH TYPE 2 DIABETES

 

Phattarabenjapol S1, Plake KS2, Modi A2, Carney Doebbeling C3, Thomas J2
1Ubon Ratchathani University, Warin Chamrab, Ubon Ratchathani, Thailand, 2Purdue University, West Lafayette, IN, USA, 3Office of Medicaid Policy and Planning, Indianapolis, IN, USA

PDB57

IMPROVING CLINICAL OUTCOMES FOR EMPLOYEES PARTICIPATING IN A PHARMACIST PROVIDED MTM

 

Pinto S1, Partha G1, Ferrell M1, Coehrs B2, Riepenhoff C2
1University of Toledo, Toledo, OH, USA, 2Pharmacy Counter, Toledo, OH, USA

PDB58

WITHDRAWN

 

 

PDB59

TIME TO OPIOID USE AMONG COMMERCIALLY-INSURED PATIENTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN WHO INITIATED DULOXETINE VERSUS OTHER TREATMENTS

 

Zhao Y1, Chen SY2, Boulanger L2, Fraser K2, Wu N2
1Eli Lilly and Company, Indianapolis, IN, USA, 2Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA

PDB60

GAPS IN MEDICAID COVERAGE AND THE RISK FOR HOSPITALIZATION AND MORTALITY AMONG INDIVIDUALS WITH DIABETES IN A MEDICAID PROGRAM

 

Yang Y, Banahan BF, Pace PF
University of Mississippi, University, MS, USA

PDB61

RACIAL AND ETHNIC DISPARITIES IN QUALITY OF HEALTH CARE AMONG ADULTS WITH DIABETES IN THE UNITED STATES IN 2005 AND 2006

 

Zhang YJ1, Holiday-Goodman M2, Amialchuk A2, Jung R2
1University of Cincinnati, Cincinnati, OH, USA, 2University of Toledo, Toledo, OH, USA

PDB62

EFFECTS OF HEALTH INSURANCE PLAN TYPE ON HEALTH CARE RESOURCE UTILIZATION IN ADULT WORKING AGE PATIENTS WITH TYPE 2 DIABETES MELLITUS

 

Kirk JR1, Campbell C1, Vivian F1, Zhao Y1, Olukotun AY2, Shi L1
1Tulane University, New Orleans, LA, USA, 2CarioVax, LLC, Princeton, NJ, USA

PDB63

COMPARATIVE RESULTS ON EFFECTS OF TYPES OF INSURANCE AND PAYMENT PLANS ON PHYSICIANS'COST AWARENESS DURING THE PHYSICIAN VISIT USING THE NAMCS SURVEY IN 1996 AND 2005

 

Huttin C1, Wong D2
1ENDEPUSresearch , Inc and University Aix Marseille III, Cambridge, MA, USA, 2ENDEPUSresearch,Inc, Cambridge, MA, USA

PDB64

USING DECISION MODELING TO DETERMINE COST-EFFECTIVENESS OF PHARMACIST INTERVENTIONS FOR PATIENTS WITH DIABETES

 

Pinto S, Holl S
University of Toledo, Toledo, OH, USA

PDB65

IMPROVED PATIENT OUTCOMES RESULTING FROM PHYSICIANS' THERAPY DECISIONS BASED ON PHARMACISTS' RECOMMENDATIONS

 

Pinto S, Blazejewski L, Holl S
University of Toledo, Toledo, OH, USA

PDB66

EVALUATION OF SELECTED COMPREHENSIVE DIABETES CARE MEASURES IN A MANAGED CARE DATABASE BY USING THE RETROSPECTIVE ANALYSIS FOR DIABETES ACTION AND REPORTING TOOL

 

Aranda G1, Colayco D2, Kamalakar R3
1Takeda Pharmaceuticals North America, Inc., Deerfield, IL, USA, 2University of Southern California, Los Angeles, CA, USA, 3Takeda Pharmaceuticals International, Deerfield, IL, USA

PDB67

ECONOMIC EVALUATION OF TYPE 2 DIABETES - IMPACT OF PRICING AND REIMBURSEMENT REFORMS

 

Ilavska A1, Glatz P2, Hloska A3, Filko M4
1Medispektrum, Bratislava, Slovak Republic, 2Janssen-Cilag, Bratislava, Slovak Republic, 3Ministry of Health, Bratislava, Slovak Republic, 4Ministry of Finance, Bratislava, Slovak Republic

PDB68

WITHDRAWN

 

 

PDB69

OLDER PATIENTS WITH NEWLY DIAGNOSED TYPE 2 DIABETES (T2DM) EXPERIENCE MORE DELAYED TREATMENT WITH ORAL ANTIHYPERGLYCEMIC AGENTS COMPARED WITH YOUNGER PATIENTS

 

Zhang Q1, Rajagopalan S2, Marrett E1, Radican L1
1Merck, Whitehouse Station, NJ, USA, 2MedData Analytics, Inc., Williamsville, NY, USA

PDB70

EVALUATION OF SITAGLIPTIN DOSING AMONG RENAL IMPAIRED TYPE 2 DIABETES MELLITUS PATIENTS

 

Krishnarajah G, Dezii C, Tran M, Balar BA
Bristol Myers Squibb, Plainsboro, NJ, USA

PDB71

WITHDRAWN

 

 

PDB72

POTENTIALLY PREVENTABLE HOSPITALIZATIONS FOR DIABETES COMPLICATIONS, CARE ORGANIZATION AND CONTINUITY OF CARE

 

Modi A1, Carney Doebbeling C2, Thomas III J1
1Purdue University, West Lafayette, IN, USA, 2Office of Medicaid Policy and Planning, Indianapolis, IN, USA

PDB73

QUALITY OF CARE FOR DIABETICS IN KARACHI PAKISTAN

 

Khowaja S1, Khowaja LA2
1Aga Khan University, Karachi, Sindh, Pakistan, 2Aga Khan University, Karachi, Pakistan

PDB74

TREATMENT OF TYPE 2 DIABETES VS. CLINICAL GUIDELINES

 

Tempas K, Skovira M, Kohli P, Wu Y
Catalina Health Resource, Blue Bell, PA, USA

PDB75

EFFECTS OF STATIN THERAPY ON HOSPITALIZATION AND MORTALITY IN PATIENTS WITH DIABETES: A RETROSPECTIVE COHORT STUDY

 

Yang Y1, Banahan BF1, Pace PF2
1University of Mississippi, University, MS, USA, 2University of Mississippi, Oxford, MS, USA

DIABETES/ENDOCRINE DISORDERS Conceptual Papers & Research on Methods

PDB76

AN OPEN-SOURCE, INTERACTIVE MODEL TO ASSESS THE OUTCOMES AND ECONOMICS OF DIABETES INTERVENTIONS IN CANADA

 

Hornberger J1, Shewade A1, Rickert JB1, Hammer M2, Groleau D3, Adams J3
1Cedar Associates LLC, Menlo Park, CA, USA, 2Novo Nordisk A/S, Bagsvaerd, Denmark, 3Novo Nordisk Canada Inc., Mississauga, ON, Canada

PDB77

IDENTIFYING THE UNDERLYING FACTORS FOR DIABETES CARE AND ATTITUDES

 

Beaton SJ1, Sperl-Hillen JM2, Davis HT1, Von Worley A1, Fernandes OD2, Baumer D1, Spain V3
1LCF Research, Albuquerque, NM, USA, 2HealthPartners Research Foundation, Minneapolis, MN, USA, 3Merck & co., Inc., North Wales, PA, USA

PDB78

RANDOMIZED CLINICAL TRIAL (RCT) DESIGN AND ANALYTIC ISSUES IMPACTING ASSUMED CLINICAL EFFECTS AND RESULTS OF COST-EFFECTIVENESS ANALYSES: ILLUSTRATION FROM A RECENT CANADIAN REPORT ON THE COST-EFFECTIVENESS OF BLOOD GLUCOSE TEST STRIPS FOR TYPE 2 DIABETES

 

Tunis S
IMS Health Inc., Falls Church, VA, USA

POSTER PRESENTATIONS SESSION I
SET-UP: Monday, May 17, 2010 – 7:30AM – 8:00AM
POSTER DISPLAY HOURS: Monday, May 17, 2010 – 8:00AM – 8:30PM
POSTER AUTHOR DISCUSSION HOUR: Monday, May 17, 20106:30PM – 7:30PM
DISMANTLE: Monday, May 17, 2010 – 8:30PM – 9:00PM

GASTROINTESTINAL DISORDERSClinical Outcomes Studies

PGI1

ASSOCIATION OF WARFARIN, NSAIDS, AND GASTROINTESTINAL BLEED

 

Smith K1, Brown S1, Malone D1, Warholak TL2
1University of Arizona, Tucson, AZ, USA, 2The University of Arizona, Tucson, AZ, USA

PGI2

ADVERSE EVENTS OF PROMETHAZINE AND ONDANSETRON IN YOUNG CHILDREN AND WOMEN OF CHILD-BEARING AGE: A PHARMACOVIGILANCE STUDY BASED ON THE FDA ADVERSE EVENT REPORTING SYSTEM

 

Seddoh SA1, Guo JJ2, Ajayi FO3, Wigle P1
1University of Cincinnati, Cincinnati, OH, USA, 2University of Cincinnati Medical Center, Cincinnati, OH, USA, 3Procter & Gamble Company, Mason, OH, USA

PGI3

PREVALENCE, COSTS AND SERVICES OF COMORBID CONDITIONS ASSOCIATED WITH FUNCTIONAL DYSPEPSIA

 

Brook RA1, Talley NJ2, Choung RS3, Smeeding J4, Melkonian AK5, Kleinman NL6
1The JeSTARx Group, Newfoundland, NJ, USA, 2Mayo Clinic Jacksonville, FL, Rochester, MN, USA, 3Mayo Clinic, Rochester, MN, USA, 4JeSTARx Group, Dallas, TX, USA, 5HCMS Group, Cheyenne, WY, USA, 6HCMS Group, Paso Robles, CA, USA

PGI4

SYSTEMATIC REVIEW AND META-ANALYSIS OF PUBLISHED RANDOMIZED CONTROLLED TRIALS COMPARING THE EFFICACY OF PEGINTERFERON-ALPHA-2A VERSUS PEGINTERFERON ALPHA-2B BOTH PLUS RIBAVIRIN IN CHRONIC HEPATITIS C PATIENTS

 

Cheinquer H1, Barros FMR2, Borges LG3, Santos E3, Buschinelli CT3
1Hospital das Clínicas da Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 2Hospital Português de Beneficência em Pernambuco and Hospital das Clínicas - UFPE, Recife, Brazil, 3Roche Brazil, São Paulo, Brazil

PGI5

A META-ANALYSIS OF THE 5-HT3 RECEPTOR ANTAGONISTS USE IN POST-OPERATIVE NAUSEA AND VOMITING PROPHYLAXIS

 

Tang D1, Malone DC2
1University of Arizona, Tucson, AZ, USA, 2University of Arizona, College of Pharmacy, Tucson, AZ, USA

PGI6

TEMPORAL CHANGES IN SURGICAL PROCEDURES FOR MANAGEMENT OF DIVERTICULAR DISEASE

 

Chung JK, Knight TK, Nichol MB
University of Southern California, Los Angeles, CA, USA

PGI7

LOW PREVALENCE OF HEPATITIS C VIRUS (HCV) DIAGNOSIS IN US HEALTH CARE DATA

 

Iwasaki K1, Velez FF2, Fitch K1, Pyenson B1
1Milliman Inc., New York, NY, USA, 2Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA

PGI8

WITHDRAWN

GASTROINTESTINAL DISORDERS Cost Studies

PGI9

A BUDGET IMPACT MODEL TO EVALUATE MEDICATION PERSISTENCE AND ASSOCIATED HEALTH CARE COSTS

 

Cohen RD1, Yen L2, Nichol MB3, McDermott JD4, Sharma G4, Knight TK3, Schaefer C4, Hodgkins P2
1The University of Chicago Medical Center, Chicago, IL, USA, 2Shire Pharmaceuticals, Wayne, PA, USA, 3University of Southern California, Los Angeles, CA, USA, 4Covance Market Access Services Inc., Gaithersburg, MD, USA

PGI10

PATIENT FINANCIAL BURDEN, SURGICAL COSTS AND REIMBURSEMENTS FOR OPEN AND LAPAROSCOPIC COLECTOMY PROCEDURES IN DIVERTICULAR DISEASE

 

Chung JK, Knight TK, Nichol MB
University of Southern California, Los Angeles, CA, USA

PGI11

PEDIATRIC HOSPITALIZATIONS FOR INFLAMMATORY BOWEL DISEASE: RESULTS FROM 2006 KIDS' INPATIENT DATABASE

 

Tundia N, Heaton PC, Kelton CM
University of Cincinnati, Cincinnati, OH, USA

PGI12

FUNCTIONAL DYSPEPSIA DECREASE PRODUCTIVITY AND INCREASED MEDICAL COSTS

 

Brook RA1, Kleinman NL2, Choung RS3, Melkonian AK4, Smeeding J5, Talley NJ6
1The JeSTARx Group, Newfoundland, NJ, USA, 2HCMS Group, Paso Robles, CA, USA, 3Mayo Clinic, Rochester, MN, USA, 4HCMS Group, Cheyenne, WY, USA, 5JeSTARx Group, Dallas, TX, USA, 6Mayo Clinic Jacksonville, FL, Rochester, MN, USA

PGI13

THE DISEASE BURDEN OF IRRITABLE BOWEL SYNDROME IN KOREA

 

Kim Y1, Jang B1, Park S1, Park J1, Nam M1, Jung HK2, Choi MG3
1National Evidence-based healthcare Collaborating Agency, Seoul, South Korea, 2Ewha Womans University School of Medicine, Seoul, South Korea, 3College of Medicine, The Catholic University of Korea, Seoul, South Korea

PGI14

DIRECT AND INDIRECT COSTS OF HEPATITIS C VIRUS (HCV): COMPARISON OF NON-HCV, UNTREATED HCV, AND PEG-RBV TREATED HCV COHORTS

 

Bonafede M1, Pan K1, Wilson K1, Solomon M2, Spiegel B3, Beam C4, Chakravarti P5
1Thomson Reuters, Cambridge, MA, USA, 2Stanford School of Medicine, Stanford, CA, USA, 3David Geffen School of Medicine at UCLA, Los Angeles, CA, USA, 4Human Genome Sciences, Inc., Rockville, MD, USA, 5Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

PGI15

MEDICAL SERVICE UTILIZATION AND COSTS BY DISEASE SEVERITY, SUSTAINED VIRAL RESPONSE, AND GENOTYPE IN EUROPEAN PATIENTS WITH CHRONIC HEPATITIS C VIRUS

 

Davis KL1, Mitra D1, Leteneux C2, Bapat B1, Naujoks C2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Novartis Pharma AG, Basel, Switzerland

PGI16

PATTERNS OF LUBIPROSTONE UTILIZATION AND COSTS IN MEMBERS OF A LARGE HEALTH BENEFITS COMPANY

 

Sussman D1, Tamariz L1, Droege M2, Harkins T3, Ma Q3, Uribe C3, Hanna JW4
1University of Miami Leonard Miller School of Medicine, Miami, FL, USA, 2Takeda Pharmaceuticals America, Deerfield, IL, USA, 3University of Miami Humana Health Services Research Center, Miami, FL, USA, 4Navigenics Inc, Foster City, CA, USA

PGI17

COST-EFFECTIVENESS ANALYSIS OF TREATMENT WITH PEGINTERFERON-ALFA-2A VERSUS PEGINTERFERON-ALFA-2B FOR PATIENTS WITH GENOTYPES 2/3 CHRONIC HEPATITIS C UNDER THE PUBLIC PAYER PERSPECTIVE IN BRAZIL

 

Barros FMR1, Cheinquer H2, Borges LG3, Santos E3
1Hospital Português de Beneficência em Pernambuco and Hospital das Clínicas - UFPE, Recife, Brazil, 2Hospital das Clínicas da Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 3Roche Brazil, São Paulo, Brazil

PGI18

COST-EFFECTIVENESS ANALYSIS OF TREATMENT WITH PEGINTERFERON-ALFA-2A VERSUS PEGINTERFERON-ALFA-2B FOR PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C UNDER THE PUBLIC PAYER PERSPECTIVE IN BRAZIL

 

Barros FMR1, Cheinquer H2, Borges LG3, Santos E3
1Hospital Português de Beneficência em Pernambuco and Hospital das Clínicas - UFPE, Recife, Brazil, 2Hospital das Clínicas da Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 3Roche Brazil, São Paulo, Brazil

PGI19

COST-EFFECTIVENESS ANALYSIS OF TREATMENT WITH PEGINTERFERON-ALFA-2A VERSUS PEGINTERFERON-ALFA-2B FOR PATIENTS WITH GENOTYPES 2/3 CHRONIC HEPATITIS C UNDER THE PRIVATE PAYER PERSPECTIVE IN BRAZIL

 

Barros FMR1, Cheinquer H2, Borges LG3, Santos E3
1Hospital Português de Beneficência em Pernambuco and Hospital das Clínicas - UFPE, Recife, Brazil, 2Hospital das Clínicas da Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 3Roche Brazil, São Paulo, Brazil

PGI20

WITHDRAWN

PGI21

ECONOMIC ANALYSIS OF ALVIMOPAN FOR PREVENTION AND MANAGEMENT OF POST-OPERATIVE ILEUS

 

Yang Y1, Touchette DR1, Tiryaki F1, Galanter W2
1University of Illinois at Chicago, Chicago, IL, USA, 2The University of Illinois at Chicago, Chicago, IL, USA

PGI22

EVALUATION OF COST-EFFECTIVENESS OF CHRONIC HEPATITIS B TREATMENTS: ENTECAVIR AND TELBIVUDINE

 

Suh JK, Hay J
University of Southern California, Los Angeles, CA, USA

PGI23

COST EFFECTIVENESS ANALYSIS OF RIFAXIMIN FOR THE TREATMENT OF ACUTE HEPATIC ENCEPHALOPATHY

 

Rivas R1, Cerezo O2, Zapata L1
1Guia Mark, Mexico, DF, Mexico, 2Instituto Nacional de Cancerología, Mexico, DF, Mexico

PGI24

COST UTILITY ANALYSIS OF CERTOLIZUMAB PEGOL VERSUS NATALIZUMB MAINTENANCE THERAPY FOR CROHN'S DISEASE

 

Wu B
University of Florida, Gainesville, FL, USA

PGI25

PHARMACOECONOMIC ANALYSIS OF THE EFFECTS OF SECONDARY BACTERIAL RESISTANCE IN THE MULTI-DEPARTMENTAL HOSPITAL ON TREATMENT EFFICACY IN COMPLICATED ABDOMINAL INFECTIONS

 

Kolbin AS1, Sidorenko S2, Zagorodnikova K1, Klimko N3, Koroleva O1
1Saint -Petersburg State University, Saint Petersburg, Russia, 2Ñhildren Infections Research Institute, Saint Petersburg, Russia, 3Saint - Petersburg Medical Academy of Postgraduate Education, Saint Petersburg, Russia

PGI26

CANADIAN COST-UTILITY ANALYSIS OF INITIATION AND MAINTENANCE TREATMENT WITH ANTI-TNF DRUGS FOR REFRACTORY CROHN'S DISEASE

 

Blackhouse G1, Xie F1, Assasi N1, Gaebel K2, Marshall J3, Irvine EJ4, Robertson D1, Goeree R1
1PATH Research Institute, McMaster University, Hamilton, ON, Canada, 2St Joseph's Healthcare, Hamilton, ON, Canada, 3Hamilton Health Sciences,McMaster University, Hamilton, ON, Canada, 4St. Michael's Hospital, University of Toronto, Toronto, ON, Canada

PGI27

OPEN VERSUS LAPAROSCOPIC PROCEDURES FOR CHOLECYSTECTOMY SURGERY: A COST-UTILITY ANALYSIS, UNDER THE BRAZILIAN PUBLIC PAYER PERSPECTIVE

 

Nasciben V1, Saggia MG1, Sanchez JF2
1Johnson & Johnson, Sao Paulo-SP, Brazil, 2Johnson & Johnson, Bogota, Colombia

PGI28

UTILIZATION AND COST OF PEGINTERFERON PLUS RIBAVIRIN COMBINATION THERAPY IN THE MANAGEMENT OF CHRONIC HEPATITIS C VIRUS IN EUROPE

 

Davis KL1, Mitra D1, Leteneux C2, Bapat B1, Naujoks C2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Novartis Pharma AG, Basel, Switzerland

GASTROINTESTINAL DISORDERS Patient-Reported Outcomes Studies

PGI29

SELECTING CHRONIC CONSTIPATION (CC) CLINICAL TRIAL ENDPOINTS: INCORPORATING THE PATIENT'S VOICE

 

Ervin CM1, Fehnel SE1, Carson RT2, Kurtz CB3, Shiff SJ2, Johnston JM3
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Forest Research Institute, Jersey City, NJ, USA, 3Ironwood Pharmaceuticals, Cambridge, MA, USA

PGI30

PSYCHOMETRIC PROPERTIES OF THE TREATMENT SATISFACTION QUESTIONNAIRE FOR MEDICATION IN PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE

 

Bharmal M1, Cascade E2, Gemmen E1
1Quintiles, Falls Church, VA, USA, 2iGuard, Falls Church, VA, USA

PGI31

PAIN AFTER LIVER TRANSPLANT: A CROSS SECTIONAL STUDY

 

Cavanaugh TM1, Waddell D1, Gorevski E1, Gutman K1, Neff GW2, Rudich SM2, Martin-Boone J1
1James L Winkle College of Pharmacy, Cincinnati, OH, USA, 2The University Hospital, Cincinnati, OH, USA

PGI32

CORRESPONDENCE OF MULTIPLE HEALTH OUTCOMES MEASURES IN RESPONSIVENESS TO MMXTM MESALAMINE TREATMENT FOR PATIENTS WITH ULCERATIVE COLITIS

 

Yen L1, Yarlas A2, Hodgkins P1
1Shire Pharmaceuticals, Wayne, PA, USA, 2QualityMetric Inc., Lincoln, RI, USA

PGI33

CURRENT EVIDENCE REGARDING THE HEPATITIS C PATIENT EXPERIENCE

 

Bauch PM1, Sterling RK2, Clement LM1, Velez FF3
1KJT Group LLC, Honeoye Falls, NY, USA, 2Virginia Commonwealth University, Richmond, VA, USA, 3Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA

PGI34

TREATMENT SATISFACTION WITH MEDICATIONS FOR GASTROESOPHAGEAL REFLUX DISEASE: RESULTS FROM A LARGE DISEASE REGISTRY

 

Bharmal M1, Cascade E2, Thiny M3
1Quintiles, Falls Church, VA, USA, 2iGuard, Falls Church, VA, USA, 3Quintiles, Morrisville, NC, USA

GASTROINTESTINAL DISORDERSHealth Care Use & Policy Studies

PGI35

PROTON PUMP INHIBITOR USE IN SENIORS: AN ANALYSIS FOCUSING ON DRUG CLAIMS 2001 TO 2008

 

Hunt J, Gaucher M
Canadian Institute for Health Information, Ottawa, ON, Canada

PGI36

USING PROPENSITY SCORE MATCHING TO ESTIMATE DIFFERENCES IN HEALTH CARE UTILIZATION BETWEEN PEOPLE WITH AND WITHOUT ULCERATIVE COLITIS

 

Thanh NX, Ohinmaa A, Jacobs P
Institute of Health Economics, Edmonton, AB, Canada

PGI37

FACTORS ASSOCIATED WITH THE USE OF ENTERAL AND PARENTERAL PROTON PUMP INHIBITOR USE IN CRITICALLY ILL PATIENTS

 

Sankaranarayanan J, Olsen KM, Reardon T, Hays EM, Orwe LA
University of Nebraska Medical Center, Omaha, NE, USA

POSTER PRESENTATIONS SESSION I
SET-UP: Monday, May 17, 2010 – 7:30AM – 8:00AM
POSTER DISPLAY HOURS: Monday, May 17, 2010 – 8:00AM – 8:30PM
POSTER AUTHOR DISCUSSION HOUR: Monday, May 17, 20106:30PM – 7:30PM
DISMANTLE: Monday, May 17, 2010 – 8:30PM – 9:00PM

URINARY/KIDNEY DISORDERSClinical Outcomes Studies

PUK1

INCIDENCE AND COST OF ADVERSE EVENTS (AES) IN PATIENTS WITH RENAL CELL CARCINOMA (RCC) TREATED WITH ANGIOGENESIS INHIBITORS (AIS)

 

Dial E1, Duh MS1, Antras L1, Rodermund D1, Neary MP2, Choueiri TK3, Oh WK4
1Analysis Group, Inc., Boston, MA, USA, 2GlaxoSmithKline, Collegeville, PA, USA, 3Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA, USA, 4Mount Sinai School of Medicine, New York, NY, USA

PUK2

RETROSPECTIVE DATABASE EVALUATION OF PATIENT CHARACTERISITICS AND HEALTH CARE UTILIZATION OF MEMBERS WITH STAGE 3 CHRONIC KIDNEY DISEASE WITH ANEMIA

 

Prasla K1, Godley PJ1, DSylva L2
1Scott & White Health Plan, Temple, TX, USA, 2American Regent, Shirley, NY, USA

PUK3

EVALUATION OF SIMULTANEOUS LIVER KIDNEY TRANSPLANTATION VERSUS LIVER TRANSPLANTATION ALONE FOR END-STAGE LIVER DISEASE PATIENTS WITH IMPAIRED RENAL FUNCTION – A COMPARATIVE EFFECTIVENESS ANALYSIS

 

Chang Y, Skaro AI, Jay C, Manheim LM
Northwestern University, Chicago, IL, USA

PUK4

EFFECT OF ATYPICAL ANTIPSYCHOTICS ON URINARY INCONTINENCE IN US NURSING HOME RESIDENTS USING PSYCHOTROPIC MEDICATIONS

 

Khokhawalla I1, Wu WK2
1St. John's University, Fresh Meadows, NY, USA, 2St.John's University, Queens, NY, USA

PUK5

DOES RACIAL VARIATION IN RISK FACTORS HAVE A ROLE TO PLAY IN THE INCIDENCE OF CHRONIC KIDNEY DISEASE IN THE US POPULATION

 

Shah J, Nair R
St.John's University, Jamaica, NY, USA

URINARY/KIDNEY DISORDERSCost Studies

PUK6

FIVE-YEAR BUDGET IMPACT ANALYSIS OF ONCE-DAILY VERSUS TWICE-DAILY TACROLIMUS, IN PATIENTS UNDERGOING RENAL TRANSPLANT IN THE UNITED KINGDOM

 

Sidhu M1, Lees L2, Warner J2
1Astellas Pharma Europe Ltd, Staines, Middlesex, UK, 2Abacus International, Bicester, Oxfordshire, UK

PUK7

IMMUNOSUPPRESSANT THERAPY PATTERNS AND ITS COSTS IN POST KIDNEY TRANSPLANT PATIENTS IN THE NATIONAL TRANSPLANT PROGRAM IN BRAZIL

 

Tedesco-Silva Jr H1, Manfro RC2, Asano E3, Nita ME3, Carvalho F3, Dan S4, Donato BM5, Rahal E3, The KIT73 STUDY GROU P3
1Fundação Oswaldo Ramos - Hospital do Rim e Hipertensão, São Paulo, São Paulo, Brazil, 2Hospital de Clínicas de Porto Alegre, São Paulo, São Paulo, Brazil, 3Bristol-Myers Squibb S/A, São Paulo, São Paulo, Brazil, 4New BD Assessoria Empresarial LTDA, São Paulo, São Paulo, Brazil, 5Bristol-Myers Squibb Co, Wallingford, CT, USA

PUK8

ERYTHROPOIESIS-STIMULATING AGENTS UTILIZATION AND COSTS IN PATIENTS WITH CHRONIC KIDNEY DISEASE NOT ON DIALYSIS FROM TWO LARGE CLAIMS DATABASES

 

Lafeuille MH1, Bailey RA2, Laliberté F1, Senbetta M2, Blacksmith A1, Lefebvre P1
1Groupe d'analyse, Ltée, Montreal, QC, Canada, 2Centocor Ortho Biotech Services, LLC, Horsham, PA, USA

PUK9

SEVEN YEAR TRENDS OF PHARMACY BENEFIT ERYTHROPOIESIS-STIMULATING AGENT UTILIZATION AND COST CONSIDERATIONS OF CHRONIC KIDNEY DISEASE PATIENTS NOT ON DIALYSIS

 

Vekeman F1, Bailey RA2, Laliberté F3, Senbetta M2, McKenzie RS2, Lefebvre P3
1Analysis Group, Inc., Washington , DC, USA, 2Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 3Groupe d'analyse, Ltée, Montreal, QC, Canada

PUK10

IMPROVED RESOURCE UTILIZATION OUTCOMES ASSOCIATED WITH PREDIALYSIS USE OF PARICALCITOL FOR SECONDARY HYPERPARATHYROIDISM (SHPT)

 

Marx S1, Frye CB2, Khan SS1, Harshaw Q2, Audhya P1, Deering K2, Sterz R1
1Abbott, Abbott Park, IL, USA, 2EPI-Q, Inc., Oak Brook, IL, USA

PUK11

COST-EFFECTIVENESS ANALYSIS OF DUTASTERIDE,TAMSULOSIN AND COMBINATION THERAPY IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA

 

Bang SI, Hay J
University of Southern California, Los Angeles, CA, USA

PUK12

ECONOMIC EVALUATION ON THE USE OF OXYBUTYNIN, TOLTERODINE, AND SOLIFENACIN IN PATIENTS WITH HYPERACTIVE BLADDER

 

De Lago Acosta A1, Salinas G2, Idrovo J3, Zapata L4, Alanís A1, Rico I5
1Laboratorios Liomont, Mexico, DF, Mexico, 2Hospital Infantil de México Federico Gómez, México, DF, Mexico, 3National Institute of Public Health, Cuernavaca, Morelos, Mexico, 4Guia Mark, Mexico, DF, Mexico, 5Guia Mark SA DE CV, Mexico, DF, Mexico

PUK13

THE COST-EFFECTIVENESS OF EARLY SURGERY, ADDING BIOPSY, AND WATCHFUL WAITING IN THE MANAGEMENT OF SMALL SOLID RENAL MASSES: EVIDENCE FROM A MARKOV MODEL

 

Yu J1, Heilbrun M1, Smith K2, Zagoria R3
1University of Utah, Salt lake city, UT, USA, 2University of Pittsburgh, Pittsburgh, PA, USA, 3Wake Forest University, Winston-Salem, NC, USA

PUK14

CHALLENGES IN ASSESSING COST-EFFECTIVENESS OF THERAPIES FOR DIALYSIS PATIENTS: A CASE STUDY OF SEVELAMER FOR THE TREATMENT OF HYPERPHOSPHATEMIA

 

Grima D1, Mendelssohn D2, Airia P1, Dunn E3, Bernard L1
1Cornerstone Research Group Inc., Burlington, ON, Canada, 2Humber River Regional Hospital, Weston, ON, Canada, 3Genzyme Corporation, Cambridge, MA, USA

PUK15

COST-EFFECTIVENESS ANALYSIS OF THREE MONTHS TREATMENT WITH FESOTERODINE COMPARED TO GENERIC OXYBUTYNIN EXTENDED-RELEASE IN WOMEN WITH URINARY INCONTINENCE FROM A THIRD PARTY PAYER PERSPECTIVE

 

Blaser DA1, Kohn MJ2, Ousterhout M1
1UMass Medical School, Shrewsbury , MA, USA, 2Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA

PUK16

COST-EFFECTIVENESS ANALYSIS IN TREATING OVERACTIVE BLADDER WITH URGE INCONTINENCE IN WOMEN: A COMPARISON BETWEEN OXYBUTYNIN AND TOLTERODINE WITH EXPLORATORY ANALYSIS OF FESOTERODINE

 

Schwartz EL, Hay JW
University of Southern California, Los Angeles, CA, USA

PUK17

THE VALUE OF HYPERTENSION CONTROL TO CHRONIC KIDNEY DISEASE PREVENTION

 

Zhuo X1, Keeler E2, Wu S2, Vargas R2
1RAND Graduate School, Atlanta, GA, USA, 2RAND Corporation, Santa Monica, CA, USA

PUK18

RENAL TRANSPLANTATION VS HEMODIALYSIS-COST EFFECTIVENESS ANALYSIS

 

Perovich S
Serbian Medical Society-Health Management Committee, Belgrade, Serbia and Montenegro

PUK19

ECONOMIC EVALUATION OF PERITONEAL DIALYSYS COMPARED WITH HEMODIALYSIS IN PATIENTS WITH CHRONIC KIDNEY DISEASE SECONDARY TO DIABETES OR HYPERTENSION IN COLOMBIA

 

DeAntonio R1, Calderón C1, Sanabria M2, Rosselli D3
1Independent consultant, Bogota, DC, Colombia, 2Baxter RTS, Bogota, DC, Colombia, 3Universidad Jorge Tadeo Lozano, Bogota, DC, Colombia

PUK20

ECONOMIC EVALUATION OF THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA IN COLOMBIA

 

Gómez P1, Plata M2, Carreño A2, Guzmán F2, Jiménez LA3, Calderón C4, Rosselli D5
1Universidad Nacional de Colombia, Bogota, DC, Colombia, 2Fundación Santa Fe de Bogotá, Bogota, DC, Colombia, 3GSK, Bogota, DC, Colombia, 4Independent consultant, Bogota, DC, Colombia, 5Universidad Jorge Tadeo Lozano, Bogota, DC, Colombia

PUK21

POST-KIDNEY TRANSPLANT MORBIDITY RELATED RE-HOSPITALIZATIONS IN THE BRAZILIAN PUBLIC HEALTH SYSTEM: CAUSES, RESOURCES USE AND COSTS BASED ON AN ADMINISTRATIVE REGISTRY REVIEW FROM 2004 TO 2009

 

David-Neto E1, Carvalho DBM2, Asano E3, Nita M3, Carvalho F3, Dan S4, Donato BM5, Rahal E3, The KIT73 STUDY GROU P3
1Hospital das Clínicas da Faculdade de Medicina da USP, HCFMUSP, São Paulo, São Paulo, Brazil, 2Hospital Geral Bonsucesso, Rio de Janeiro, Rio de Janeiro, Brazil, 3Bristol-Myers Squibb S/A, São Paulo, São Paulo, Brazil, 4New BD Assessoria Empresarial LTDA, São Paulo, São Paulo, Brazil, 5Bristol-Myers Squibb Co, Wallingford, CT, USA

PUK22

REJECTION EPISODES REQUIRING HOSPITALIZATION AFTER KIDNEY TRANSPLANT IN BRAZIL: A RETROSPECTIVE DATABASE STUDY OF THE BRAZILIAN PUBLIC HEALTH SYSTEM

 

Duro-Garcia V1, Abbud-Filho M2, Esmeraldo RM3, Asano E4, Nita M4, Carvalho F4, Dan S5, Donato BM6, Rahal E4, The KIT73 STUDY GROUP4
1Universidade Federal de Ciências da Saúde de Porto Alegre, UFCSPA, Porto Alegre, Rio Grande do Su, Brazil, 2FAMERP/FUNFARME Medical University, São Jose do Rio Preto, São Paulo, Brazil, 3Hospital Geral de Fortaleza, Fortaleza, Ceara, Brazil, 4Bristol-Myers Squibb S/A, São Paulo, São Paulo, Brazil, 5New BD Assessoria Empresarial LTDA, São Paulo, São Paulo, Brazil, 6Bristol-Myers Squibb Co, Wallingford, CT, USA

URINARY/KIDNEY DISORDERS Patient-Reported Outcomes Studies

PUK23

ADHERENCE TO A GUIDELINE FOR ERYTHROPOIESIS STIMULATING AGENTS IN CHRONIC KIDNEY DISEASE

 

Yeh YC1, Clapp MD2, Churchill WW3, O'Day J4, Reddy P1
1Partners Healthcare, Needham, MA, USA, 2Massachusetts General Hospital, Boston, MA, USA, 3Brigham & Women's Hospital, Boston, MA, USA, 4Faulkner Hospital, Jamaica Plain, MA, USA

URINARY/KIDNEY DISORDERS Health Care Use & Policy Studies

PUK24

THE IMPACT OF ADDING A RACIAL CASE MIX ADJUSTER TO MEDICARE DIALYSIS REMIBURSEMENT: CORRECTING A POTENTIAL BIAS

 

Mutell R1, Mayne T1, Krishnan M1, Nissenson A2
1DaVita Clinical Research, Minneapolis, MN, USA, 2DaVita Inc., El Segundo, CA, USA

PUK25

CASE MIX ADJUSTMENT: THE CONSEQUENCES OF DIVERGENCE IN ACCESS TO DATA

 

Mayne T, Burgess M, Weldon J
DaVita Clinical Research, Minneapolis, MN, USA

PUK26

THE NON-LINEAR RELATIONSHIP BETWEEN DOSING FREQUENCY AND BREAK-EVEN COSTS IN CAPITATED ESRD REIMBURSEMENT

 

Mayne T, Krishnan M, Mutell R
DaVita Clinical Research, Minneapolis, MN, USA

PUK27

ERYTHROPOIESIS-STIMULATING AGENT DOSING AND HEMOGLOBIN TRENDS OVER TIME IN CHRONIC KIDNEY DISEASE PATIENTS NOT ON DIALYSIS

 

Lafeuille MH1, Bailey RA2, Laliberté F1, Senbetta M2, Vekeman F3, McKenzie RS2, Dea K1, Lefebvre P1
1Groupe d'analyse, Ltée, Montreal, QC, Canada, 2Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 3Analysis Group, Inc., Washington , DC, USA

PUK28

ASSESSMENT OF RECENT ERYTHROPOIESIS-STIMULATING AGENT GUIDELINES CHANGES ON DOSING PATTERNS IN CHRONIC KIDNEY DISEASE PATIENTS NOT ON DIALYSIS

 

Lafeuille MH1, Bailey RA2, Laliberté F1, Senbetta M2, Vekeman F3, McKenzie RS2, Blacksmith A1, Lefebvre P1
1Groupe d'analyse, Ltée, Montreal, QC, Canada, 2Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 3Analysis Group, Inc., Washington , DC, USA

URINARY/KIDNEY DISORDERS Conceptual Papers & Research on Methods

PUK29

WITHDRAWN

 

 



15th Annual International Meeting Main Page